WO2010117435A2 - No-carrier-added nucleophilic [f-18] fluorination of aromatic compounds - Google Patents
No-carrier-added nucleophilic [f-18] fluorination of aromatic compounds Download PDFInfo
- Publication number
- WO2010117435A2 WO2010117435A2 PCT/US2010/001012 US2010001012W WO2010117435A2 WO 2010117435 A2 WO2010117435 A2 WO 2010117435A2 US 2010001012 W US2010001012 W US 2010001012W WO 2010117435 A2 WO2010117435 A2 WO 2010117435A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- och
- ocooc
- tert
- iodonium
- derivative
- Prior art date
Links
- 230000000269 nucleophilic effect Effects 0.000 title description 13
- 238000003682 fluorination reaction Methods 0.000 title description 12
- 150000001491 aromatic compounds Chemical class 0.000 title description 5
- KRHYYFGTRYWZRS-BJUDXGSMSA-N ac1l2y5h Chemical compound [18FH] KRHYYFGTRYWZRS-BJUDXGSMSA-N 0.000 claims abstract description 59
- KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 claims abstract description 56
- MGFYSGNNHQQTJW-UHFFFAOYSA-N iodonium Chemical compound [IH2+] MGFYSGNNHQQTJW-UHFFFAOYSA-N 0.000 claims abstract description 55
- 125000003118 aryl group Chemical group 0.000 claims abstract description 24
- -1 halide ions Chemical class 0.000 claims abstract description 23
- 238000010534 nucleophilic substitution reaction Methods 0.000 claims abstract description 15
- 239000002243 precursor Substances 0.000 claims abstract description 15
- 238000002360 preparation method Methods 0.000 claims abstract description 15
- JMDCRDOIPYCSCH-LURJTMIESA-N (2s)-3-(3,4-dihydroxyphenyl)-2-(fluoroamino)propanoic acid Chemical compound OC(=O)[C@@H](NF)CC1=CC=C(O)C(O)=C1 JMDCRDOIPYCSCH-LURJTMIESA-N 0.000 claims abstract description 13
- 238000005903 acid hydrolysis reaction Methods 0.000 claims abstract description 8
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 55
- 238000000034 method Methods 0.000 claims description 43
- 239000000243 solution Substances 0.000 claims description 37
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 claims description 36
- 150000001875 compounds Chemical class 0.000 claims description 23
- 238000010438 heat treatment Methods 0.000 claims description 20
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 19
- 239000000203 mixture Substances 0.000 claims description 16
- FFHWGQQFANVOHV-UHFFFAOYSA-N dimethyldioxirane Chemical compound CC1(C)OO1 FFHWGQQFANVOHV-UHFFFAOYSA-N 0.000 claims description 14
- 239000002253 acid Substances 0.000 claims description 13
- IPZJQDSFZGZEOY-UHFFFAOYSA-N dimethylmethylene Chemical group C[C]C IPZJQDSFZGZEOY-UHFFFAOYSA-N 0.000 claims description 13
- 229910052760 oxygen Inorganic materials 0.000 claims description 13
- 229910052717 sulfur Inorganic materials 0.000 claims description 12
- 125000001453 quaternary ammonium group Chemical group 0.000 claims description 11
- 125000002346 iodo group Chemical group I* 0.000 claims description 10
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 10
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 9
- 229940024606 amino acid Drugs 0.000 claims description 9
- CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical compound Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 claims description 8
- KYQCOXFCLRTKLS-UHFFFAOYSA-N Pyrazine Chemical compound C1=CN=CC=N1 KYQCOXFCLRTKLS-UHFFFAOYSA-N 0.000 claims description 8
- 150000007513 acids Chemical class 0.000 claims description 8
- 150000001413 amino acids Chemical class 0.000 claims description 7
- 238000004519 manufacturing process Methods 0.000 claims description 7
- 239000007864 aqueous solution Substances 0.000 claims description 6
- 230000008569 process Effects 0.000 claims description 6
- DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 claims description 6
- 125000005207 tetraalkylammonium group Chemical group 0.000 claims description 6
- 150000008575 L-amino acids Chemical class 0.000 claims description 5
- 229910052500 inorganic mineral Inorganic materials 0.000 claims description 5
- 150000002500 ions Chemical class 0.000 claims description 5
- 239000011707 mineral Substances 0.000 claims description 5
- 230000001590 oxidative effect Effects 0.000 claims description 5
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 5
- 125000003698 tetramethyl group Chemical group [H]C([H])([H])* 0.000 claims description 5
- XLYOFNOQVPJJNP-NJFSPNSNSA-N ((18)O)water Chemical compound [18OH2] XLYOFNOQVPJJNP-NJFSPNSNSA-N 0.000 claims description 4
- LUMNWCHHXDUKFI-UHFFFAOYSA-N 5-bicyclo[2.2.1]hept-2-enylmethanol Chemical compound C1C2C(CO)CC1C=C2 LUMNWCHHXDUKFI-UHFFFAOYSA-N 0.000 claims description 4
- PCNDJXKNXGMECE-UHFFFAOYSA-N Phenazine Natural products C1=CC=CC2=NC3=CC=CC=C3N=C21 PCNDJXKNXGMECE-UHFFFAOYSA-N 0.000 claims description 4
- 150000003862 amino acid derivatives Chemical class 0.000 claims description 4
- 238000001704 evaporation Methods 0.000 claims description 4
- 125000004407 fluoroaryl group Chemical group 0.000 claims description 4
- 239000003446 ligand Substances 0.000 claims description 4
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 4
- CPELXLSAUQHCOX-UHFFFAOYSA-M Bromide Chemical compound [Br-] CPELXLSAUQHCOX-UHFFFAOYSA-M 0.000 claims description 3
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 claims description 3
- 150000008574 D-amino acids Chemical class 0.000 claims description 3
- KSZVHVUMUSIKTC-UHFFFAOYSA-N acetic acid;propan-2-one Chemical compound CC(C)=O.CC(O)=O KSZVHVUMUSIKTC-UHFFFAOYSA-N 0.000 claims description 3
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 3
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 2
- 125000000539 amino acid group Chemical group 0.000 claims description 2
- 125000004185 ester group Chemical group 0.000 claims description 2
- 230000003301 hydrolyzing effect Effects 0.000 claims description 2
- 150000001555 benzenes Chemical class 0.000 claims 5
- 150000002367 halogens Chemical group 0.000 claims 4
- 229910052736 halogen Inorganic materials 0.000 claims 3
- 125000005843 halogen group Chemical group 0.000 claims 3
- 230000005855 radiation Effects 0.000 claims 3
- BVKZGUZCCUSVTD-UHFFFAOYSA-M Bicarbonate Chemical compound OC([O-])=O BVKZGUZCCUSVTD-UHFFFAOYSA-M 0.000 claims 2
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- 150000001412 amines Chemical class 0.000 claims 1
- 150000001732 carboxylic acid derivatives Chemical group 0.000 claims 1
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000005931 tert-butyloxycarbonyl group Chemical group [H]C([H])([H])C(OC(*)=O)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- KTNLYTNKBOKXRW-UHFFFAOYSA-N phenyliodanium Chemical compound [IH+]C1=CC=CC=C1 KTNLYTNKBOKXRW-UHFFFAOYSA-N 0.000 abstract description 22
- 239000012038 nucleophile Substances 0.000 abstract description 10
- WTDRDQBEARUVNC-LURJTMIESA-N L-DOPA Chemical class OC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-LURJTMIESA-N 0.000 abstract description 6
- 230000000694 effects Effects 0.000 abstract description 6
- 125000006575 electron-withdrawing group Chemical group 0.000 abstract description 6
- 239000000543 intermediate Substances 0.000 abstract description 5
- 125000001153 fluoro group Chemical group F* 0.000 abstract description 4
- WTDRDQBEARUVNC-UHFFFAOYSA-N L-Dopa Natural products OC(=O)C(N)CC1=CC=C(O)C(O)=C1 WTDRDQBEARUVNC-UHFFFAOYSA-N 0.000 abstract description 3
- 125000003106 haloaryl group Chemical group 0.000 abstract 1
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 54
- 238000006243 chemical reaction Methods 0.000 description 40
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 39
- 239000000047 product Substances 0.000 description 36
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 26
- 239000011541 reaction mixture Substances 0.000 description 26
- 238000005160 1H NMR spectroscopy Methods 0.000 description 22
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 22
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 22
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 21
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 21
- 238000000816 matrix-assisted laser desorption--ionisation Methods 0.000 description 20
- 239000011734 sodium Substances 0.000 description 19
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 18
- 230000015572 biosynthetic process Effects 0.000 description 18
- 238000003786 synthesis reaction Methods 0.000 description 18
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 16
- 235000019439 ethyl acetate Nutrition 0.000 description 14
- 239000007787 solid Substances 0.000 description 14
- 229910052786 argon Inorganic materials 0.000 description 13
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 12
- 229940093499 ethyl acetate Drugs 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
- 239000011737 fluorine Substances 0.000 description 9
- 229910052731 fluorine Inorganic materials 0.000 description 9
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 8
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 8
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 8
- 239000012044 organic layer Substances 0.000 description 7
- 239000000741 silica gel Substances 0.000 description 7
- 229910002027 silica gel Inorganic materials 0.000 description 7
- 239000000725 suspension Substances 0.000 description 7
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 6
- 239000007832 Na2SO4 Substances 0.000 description 6
- 239000003480 eluent Substances 0.000 description 6
- 238000002290 gas chromatography-mass spectrometry Methods 0.000 description 6
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical class I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 6
- 229910052938 sodium sulfate Inorganic materials 0.000 description 6
- 239000002904 solvent Substances 0.000 description 6
- BBKLNJOHKDVHHI-UHFFFAOYSA-N 1-(bromomethyl)-2-iodo-4,5-bis(phenylmethoxy)benzene Chemical compound C=1C=CC=CC=1COC=1C=C(I)C(CBr)=CC=1OCC1=CC=CC=C1 BBKLNJOHKDVHHI-UHFFFAOYSA-N 0.000 description 5
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 5
- 239000000090 biomarker Substances 0.000 description 5
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 238000003818 flash chromatography Methods 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000012074 organic phase Substances 0.000 description 5
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 5
- 238000002600 positron emission tomography Methods 0.000 description 5
- 238000010898 silica gel chromatography Methods 0.000 description 5
- 238000003756 stirring Methods 0.000 description 5
- 125000001424 substituent group Chemical group 0.000 description 5
- 238000006467 substitution reaction Methods 0.000 description 5
- FVIIJYHSTMMZIA-DHIFEGFHSA-N tert-butyl (2S,5S)-2-tert-butyl-5-[[3-[(2-iodophenyl)methoxy]-4-phenylmethoxyphenyl]methyl]-3-methyl-4-oxoimidazolidine-1-carboxylate Chemical compound C(C)(C)(C)OC(=O)N1[C@H](N(C([C@@H]1CC1=CC=C(C(=C1)OCC1=C(C=CC=C1)I)OCC1=CC=CC=C1)=O)C)C(C)(C)C FVIIJYHSTMMZIA-DHIFEGFHSA-N 0.000 description 5
- IZXIZTKNFFYFOF-UHFFFAOYSA-N 2-Oxazolidone Chemical compound O=C1NCCO1 IZXIZTKNFFYFOF-UHFFFAOYSA-N 0.000 description 4
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical group [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- MZRVEZGGRBJDDB-UHFFFAOYSA-N N-Butyllithium Chemical compound [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 4
- LADVXQNFPXBLDY-UHFFFAOYSA-N [3,4-bis(phenylmethoxy)phenyl]methanol Chemical compound C=1C=CC=CC=1COC1=CC(CO)=CC=C1OCC1=CC=CC=C1 LADVXQNFPXBLDY-UHFFFAOYSA-N 0.000 description 4
- 238000010533 azeotropic distillation Methods 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 229910052739 hydrogen Inorganic materials 0.000 description 4
- SNHMUERNLJLMHN-UHFFFAOYSA-N iodobenzene Chemical compound IC1=CC=CC=C1 SNHMUERNLJLMHN-UHFFFAOYSA-N 0.000 description 4
- 238000000746 purification Methods 0.000 description 4
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 4
- JQWHASGSAFIOCM-UHFFFAOYSA-M sodium periodate Chemical compound [Na+].[O-]I(=O)(=O)=O JQWHASGSAFIOCM-UHFFFAOYSA-M 0.000 description 4
- UFDULEKOJAEIRI-UHFFFAOYSA-N (2-acetyloxy-3-iodophenyl) acetate Chemical compound CC(=O)OC1=CC=CC(I)=C1OC(C)=O UFDULEKOJAEIRI-UHFFFAOYSA-N 0.000 description 3
- WFDIJRYMOXRFFG-UHFFFAOYSA-N Acetic anhydride Chemical compound CC(=O)OC(C)=O WFDIJRYMOXRFFG-UHFFFAOYSA-N 0.000 description 3
- WMFOQBRAJBCJND-UHFFFAOYSA-M Lithium hydroxide Chemical compound [Li+].[OH-] WMFOQBRAJBCJND-UHFFFAOYSA-M 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 3
- 239000012267 brine Substances 0.000 description 3
- 229910052799 carbon Inorganic materials 0.000 description 3
- UAOMVDZJSHZZME-UHFFFAOYSA-N diisopropylamine Chemical compound CC(C)NC(C)C UAOMVDZJSHZZME-UHFFFAOYSA-N 0.000 description 3
- 150000002148 esters Chemical class 0.000 description 3
- NULMGOSOSZBEQL-QMMMGPOBSA-N etilevodopa Chemical compound CCOC(=O)[C@@H](N)CC1=CC=C(O)C(O)=C1 NULMGOSOSZBEQL-QMMMGPOBSA-N 0.000 description 3
- 239000006260 foam Substances 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 239000005457 ice water Substances 0.000 description 3
- 229910052740 iodine Inorganic materials 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 150000003254 radicals Chemical class 0.000 description 3
- 239000012047 saturated solution Substances 0.000 description 3
- HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 3
- ZGGHJBUCYSKPKC-LBNVMWSVSA-N (2S,5R)-2-[[3-[(2-iodophenyl)methoxy]-4-phenylmethoxyphenyl]methyl]-3,6-dimethoxy-5-propan-2-yl-2,5-dihydropyrazine Chemical compound COC=1[C@H](N=C([C@@H](N1)CC1=CC=C(C(=C1)OCC1=C(C=CC=C1)I)OCC1=CC=CC=C1)OC)C(C)C ZGGHJBUCYSKPKC-LBNVMWSVSA-N 0.000 description 2
- FCFWEOGTZZPCTO-MRVPVSSYSA-N (2r)-3,6-dimethoxy-2-propan-2-yl-2,5-dihydropyrazine Chemical compound COC1=N[C@H](C(C)C)C(OC)=NC1 FCFWEOGTZZPCTO-MRVPVSSYSA-N 0.000 description 2
- XDDLXZHBWVFPRG-UHFFFAOYSA-N 3,4-bis(phenylmethoxy)benzaldehyde Chemical compound C=1C=CC=CC=1COC1=CC(C=O)=CC=C1OCC1=CC=CC=C1 XDDLXZHBWVFPRG-UHFFFAOYSA-N 0.000 description 2
- PVFOHMXILQEIHX-UHFFFAOYSA-N 8-[(6-bromo-1,3-benzodioxol-5-yl)sulfanyl]-9-[2-(2-bromophenyl)ethyl]purin-6-amine Chemical compound C=1C=2OCOC=2C=C(Br)C=1SC1=NC=2C(N)=NC=NC=2N1CCC1=CC=CC=C1Br PVFOHMXILQEIHX-UHFFFAOYSA-N 0.000 description 2
- 0 Cc1cc(*)c(*)cc1C[C@@]1N(*)COC1=O Chemical compound Cc1cc(*)c(*)cc1C[C@@]1N(*)COC1=O 0.000 description 2
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- ZMXDDKWLCZADIW-YYWVXINBSA-N N,N-dimethylformamide-d7 Chemical compound [2H]C(=O)N(C([2H])([2H])[2H])C([2H])([2H])[2H] ZMXDDKWLCZADIW-YYWVXINBSA-N 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical group C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- RDOXTESZEPMUJZ-UHFFFAOYSA-N anisole Chemical compound COC1=CC=CC=C1 RDOXTESZEPMUJZ-UHFFFAOYSA-N 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 150000004945 aromatic hydrocarbons Chemical class 0.000 description 2
- YCOXTKKNXUZSKD-UHFFFAOYSA-N as-o-xylenol Natural products CC1=CC=C(O)C=C1C YCOXTKKNXUZSKD-UHFFFAOYSA-N 0.000 description 2
- FJDQFPXHSGXQBY-UHFFFAOYSA-L caesium carbonate Chemical compound [Cs+].[Cs+].[O-]C([O-])=O FJDQFPXHSGXQBY-UHFFFAOYSA-L 0.000 description 2
- DOBRDRYODQBAMW-UHFFFAOYSA-N copper(i) cyanide Chemical compound [Cu+].N#[C-] DOBRDRYODQBAMW-UHFFFAOYSA-N 0.000 description 2
- 239000012043 crude product Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 description 2
- 125000003754 ethoxycarbonyl group Chemical group C(=O)(OCC)* 0.000 description 2
- 230000008020 evaporation Effects 0.000 description 2
- 239000000706 filtrate Substances 0.000 description 2
- KRHYYFGTRYWZRS-BJUDXGSMSA-M fluorine-18(1-) Chemical compound [18F-] KRHYYFGTRYWZRS-BJUDXGSMSA-M 0.000 description 2
- 238000013467 fragmentation Methods 0.000 description 2
- 238000006062 fragmentation reaction Methods 0.000 description 2
- 150000002431 hydrogen Chemical class 0.000 description 2
- 238000011835 investigation Methods 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- GXHFUVWIGNLZSC-UHFFFAOYSA-N meldrum's acid Chemical class CC1(C)OC(=O)CC(=O)O1 GXHFUVWIGNLZSC-UHFFFAOYSA-N 0.000 description 2
- UZKWTJUDCOPSNM-UHFFFAOYSA-N methoxybenzene Substances CCCCOC=C UZKWTJUDCOPSNM-UHFFFAOYSA-N 0.000 description 2
- 235000010755 mineral Nutrition 0.000 description 2
- PYLWMHQQBFSUBP-UHFFFAOYSA-N monofluorobenzene Chemical compound FC1=CC=CC=C1 PYLWMHQQBFSUBP-UHFFFAOYSA-N 0.000 description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 2
- 229960005190 phenylalanine Drugs 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 230000009257 reactivity Effects 0.000 description 2
- 235000017557 sodium bicarbonate Nutrition 0.000 description 2
- AKHNMLFCWUSKQB-UHFFFAOYSA-L sodium thiosulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=S AKHNMLFCWUSKQB-UHFFFAOYSA-L 0.000 description 2
- 235000019345 sodium thiosulphate Nutrition 0.000 description 2
- ITMCEJHCFYSIIV-UHFFFAOYSA-M triflate Chemical compound [O-]S(=O)(=O)C(F)(F)F ITMCEJHCFYSIIV-UHFFFAOYSA-M 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- PFEHWQPGNWUQJV-UHFFFAOYSA-N (3-acetyloxy-4-iodo-2-oxo-1,3-oxazolidin-4-yl) acetate Chemical class CC(=O)ON1C(=O)OCC1(I)OC(C)=O PFEHWQPGNWUQJV-UHFFFAOYSA-N 0.000 description 1
- MIOPJNTWMNEORI-GMSGAONNSA-N (S)-camphorsulfonic acid Chemical compound C1C[C@@]2(CS(O)(=O)=O)C(=O)C[C@@H]1C2(C)C MIOPJNTWMNEORI-GMSGAONNSA-N 0.000 description 1
- FMTRXPVVZQQIKN-UHFFFAOYSA-N (aminodiazenyl)benzene Chemical group NN=NC1=CC=CC=C1 FMTRXPVVZQQIKN-UHFFFAOYSA-N 0.000 description 1
- PEZNEXFPRSOYPL-UHFFFAOYSA-N (bis(trifluoroacetoxy)iodo)benzene Chemical compound FC(F)(F)C(=O)OI(OC(=O)C(F)(F)F)C1=CC=CC=C1 PEZNEXFPRSOYPL-UHFFFAOYSA-N 0.000 description 1
- QCRBVUNVJBEAGT-UHFFFAOYSA-N 1-iodoimidazolidin-2-one Chemical class IN1CCNC1=O QCRBVUNVJBEAGT-UHFFFAOYSA-N 0.000 description 1
- RKEFIAGKFJHXLF-UHFFFAOYSA-N 2-iodo-1,3-oxazolidin-5-one Chemical class IC1NCC(=O)O1 RKEFIAGKFJHXLF-UHFFFAOYSA-N 0.000 description 1
- AUFVJZSDSXXFOI-UHFFFAOYSA-N 2.2.2-cryptand Chemical compound C1COCCOCCN2CCOCCOCCN1CCOCCOCC2 AUFVJZSDSXXFOI-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- 241001120493 Arene Species 0.000 description 1
- 102000003823 Aromatic-L-amino-acid decarboxylases Human genes 0.000 description 1
- 108090000121 Aromatic-L-amino-acid decarboxylases Proteins 0.000 description 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 1
- 208000003174 Brain Neoplasms Diseases 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- 239000007848 Bronsted acid Substances 0.000 description 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 1
- 239000004215 Carbon black (E152) Substances 0.000 description 1
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 229910010084 LiAlH4 Inorganic materials 0.000 description 1
- 238000005684 Liebig rearrangement reaction Methods 0.000 description 1
- FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 1
- 238000012879 PET imaging Methods 0.000 description 1
- 229930040373 Paraformaldehyde Natural products 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- ARCJQKUWGAZPFX-KBPBESRZSA-N S-trans-stilbene oxide Chemical compound C1([C@H]2[C@@H](O2)C=2C=CC=CC=2)=CC=CC=C1 ARCJQKUWGAZPFX-KBPBESRZSA-N 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000003929 acidic solution Substances 0.000 description 1
- 230000003466 anti-cipated effect Effects 0.000 description 1
- 239000000010 aprotic solvent Substances 0.000 description 1
- 238000005693 aromatic fluorination reaction Methods 0.000 description 1
- 150000001501 aryl fluorides Chemical class 0.000 description 1
- AGEZXYOZHKGVCM-UHFFFAOYSA-N benzyl bromide Chemical compound BrCC1=CC=CC=C1 AGEZXYOZHKGVCM-UHFFFAOYSA-N 0.000 description 1
- 230000003851 biochemical process Effects 0.000 description 1
- 125000001246 bromo group Chemical group Br* 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 229910000024 caesium carbonate Inorganic materials 0.000 description 1
- 150000001721 carbon Chemical group 0.000 description 1
- 235000011089 carbon dioxide Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical class OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 150000007942 carboxylates Chemical class 0.000 description 1
- 150000001768 cations Chemical class 0.000 description 1
- 238000011097 chromatography purification Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000002739 cryptand Substances 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 239000011903 deuterated solvents Substances 0.000 description 1
- 238000003745 diagnosis Methods 0.000 description 1
- 229940043279 diisopropylamine Drugs 0.000 description 1
- 229910001873 dinitrogen Inorganic materials 0.000 description 1
- 125000000532 dioxanyl group Chemical group 0.000 description 1
- 238000006073 displacement reaction Methods 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 229960003638 dopamine Drugs 0.000 description 1
- 238000010828 elution Methods 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 238000004334 fluoridation Methods 0.000 description 1
- 239000012025 fluorinating agent Substances 0.000 description 1
- 150000002222 fluorine compounds Chemical group 0.000 description 1
- 150000008423 fluorobenzenes Chemical class 0.000 description 1
- 239000007789 gas Substances 0.000 description 1
- 239000000499 gel Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 238000005658 halogenation reaction Methods 0.000 description 1
- 229930195733 hydrocarbon Natural products 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 239000012216 imaging agent Substances 0.000 description 1
- 238000003384 imaging method Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000011850 initial investigation Methods 0.000 description 1
- 239000013067 intermediate product Substances 0.000 description 1
- 150000008424 iodobenzenes Chemical class 0.000 description 1
- 125000000468 ketone group Chemical group 0.000 description 1
- 239000010410 layer Substances 0.000 description 1
- 239000012280 lithium aluminium hydride Substances 0.000 description 1
- DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
- 229910003002 lithium salt Inorganic materials 0.000 description 1
- 159000000002 lithium salts Chemical class 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 238000001906 matrix-assisted laser desorption--ionisation mass spectrometry Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000001404 mediated effect Effects 0.000 description 1
- AUHZEENZYGFFBQ-UHFFFAOYSA-N mesitylene Substances CC1=CC(C)=CC(C)=C1 AUHZEENZYGFFBQ-UHFFFAOYSA-N 0.000 description 1
- 125000001827 mesitylenyl group Chemical group [H]C1=C(C(*)=C(C([H])=C1C([H])([H])[H])C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012544 monitoring process Methods 0.000 description 1
- PSHKMPUSSFXUIA-UHFFFAOYSA-N n,n-dimethylpyridin-2-amine Chemical compound CN(C)C1=CC=CC=N1 PSHKMPUSSFXUIA-UHFFFAOYSA-N 0.000 description 1
- 125000006501 nitrophenyl group Chemical group 0.000 description 1
- 239000000101 novel biomarker Substances 0.000 description 1
- 238000007344 nucleophilic reaction Methods 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 150000002924 oxiranes Chemical class 0.000 description 1
- 229920002866 paraformaldehyde Polymers 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- KHIWWQKSHDUIBK-UHFFFAOYSA-N periodic acid Chemical compound OI(=O)(=O)=O KHIWWQKSHDUIBK-UHFFFAOYSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- BXRNXXXXHLBUKK-UHFFFAOYSA-N piperazine-2,5-dione Chemical class O=C1CNC(=O)CN1 BXRNXXXXHLBUKK-UHFFFAOYSA-N 0.000 description 1
- 239000003880 polar aprotic solvent Substances 0.000 description 1
- 125000003367 polycyclic group Chemical group 0.000 description 1
- 229920001296 polysiloxane Polymers 0.000 description 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 230000005588 protonation Effects 0.000 description 1
- 150000008318 pyrimidones Chemical class 0.000 description 1
- 238000000163 radioactive labelling Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000011894 semi-preparative HPLC Methods 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- KZJPVUDYAMEDRM-UHFFFAOYSA-M silver;2,2,2-trifluoroacetate Chemical compound [Ag+].[O-]C(=O)C(F)(F)F KZJPVUDYAMEDRM-UHFFFAOYSA-M 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 239000012279 sodium borohydride Substances 0.000 description 1
- 229910000033 sodium borohydride Inorganic materials 0.000 description 1
- 229910000029 sodium carbonate Inorganic materials 0.000 description 1
- 239000007858 starting material Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- HJJLVATZPPJBNG-JTQLQIEISA-N tert-butyl (2s)-2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate Chemical compound CN1[C@H](C(C)(C)C)N(C(=O)OC(C)(C)C)CC1=O HJJLVATZPPJBNG-JTQLQIEISA-N 0.000 description 1
- HJJLVATZPPJBNG-UHFFFAOYSA-N tert-butyl 2-tert-butyl-3-methyl-4-oxoimidazolidine-1-carboxylate Chemical compound CN1C(C(C)(C)C)N(C(=O)OC(C)(C)C)CC1=O HJJLVATZPPJBNG-UHFFFAOYSA-N 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000005979 thermal decomposition reaction Methods 0.000 description 1
- 229930192474 thiophene Natural products 0.000 description 1
- 150000003577 thiophenes Chemical class 0.000 description 1
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- AYNNSCRYTDRFCP-UHFFFAOYSA-N triazene Chemical group NN=N AYNNSCRYTDRFCP-UHFFFAOYSA-N 0.000 description 1
- GETQZCLCWQTVFV-UHFFFAOYSA-N trimethylamine Chemical compound CN(C)C GETQZCLCWQTVFV-UHFFFAOYSA-N 0.000 description 1
- 238000000825 ultraviolet detection Methods 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D319/00—Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
- C07D319/04—1,3-Dioxanes; Hydrogenated 1,3-dioxanes
- C07D319/06—1,3-Dioxanes; Hydrogenated 1,3-dioxanes not condensed with other rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C201/00—Preparation of esters of nitric or nitrous acid or of compounds containing nitro or nitroso groups bound to a carbon skeleton
- C07C201/06—Preparation of nitro compounds
- C07C201/12—Preparation of nitro compounds by reactions not involving the formation of nitro groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C227/00—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C227/14—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof
- C07C227/16—Preparation of compounds containing amino and carboxyl groups bound to the same carbon skeleton from compounds containing already amino and carboxyl groups or derivatives thereof by reactions not involving the amino or carboxyl groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
- C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
- C07C229/34—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
- C07C229/36—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton containing six-membered aromatic rings with at least one amino group and one carboxyl group bound to the same carbon atom of the carbon skeleton
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/30—Oxygen or sulfur atoms
- C07D233/32—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D241/00—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
- C07D241/02—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
- C07D241/06—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members
- C07D241/08—Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having one or two double bonds between ring members or between ring members and non-ring members with oxygen atoms directly attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/08—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D263/16—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/18—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Definitions
- Electrophilic fluorination reactions can only provide products with low specific activities (ca 1-5 Ci/mmol) because of the unavoidable addition of non-radioactive elemental fluorine (often called carrier fluorine) during the current production techniques for F- 18 labeled fluorine.
- carrier fluorine non-radioactive elemental fluorine
- the combination of labeled fluorine and carrier fluorine is referred to as [ F] F 2 .
- a typical example of electrophilic radiofluorination can be summarized by the following reaction:
- R electron withdrawing groups (e.g. CHO, COOEt, CN, NO 2 etc) or electron donating groups (e.g. CH 3 , OCH 3 etc.)
- R electron donating groups (e.g. CH 3 , OCH 3 etc) or electron withdrawing (CHO, NO 2 , CN) group substituted at ortho, meta, para position with respect to the triazene moiety.
- electron donating groups e.g. CH 3 , OCH 3 etc
- electron withdrawing CHO, NO 2 , CN
- R 1 and R 2 electron donating (e.g. CH 3 , OCH 3 etc) or electron withdrawing (CHO, NO 2 etc) groups located at ortho, meta or para positions with respect to the iodonium moiety.
- X ⁇ triflate, tosylate or brorride.
- the radiolabeled fluorine i.e. F
- F the radiolabeled fluorine
- the phenyl ring carrying an electron withdrawing group is invariably radiofluorinated in higher yields than its counterpart phenyl ring substituted with an electron donating group.
- a novel aromatic nucleophilic halogenation reaction which proceeds without the addition or inclusion of an ion carrier is described.
- a fluorination reaction which proceeds without the addition or inclusion of an [F-18] fluoride ion carrier is set forth.
- this "no-carrier-added" [F- 18] fluoride ion is reacted with a phenyliodonium ylide derivative, with the fluoride ion nucleophilically substituting the iodonium ylide group on the aromatic ring, resulting in regiospecific F- 18 labeled aromatic compounds.
- the no-carrier-added [F- 18] fluoride ion is produced by proton irradiation of [0-18] water using a cyclotron.
- the [F- 18] fluoride ion is then treated with potassium carbonate and a Kryptofix ® ligand and the aqueous solution is evaporated.
- the residue is further dried using azeotropic distillation with acetonitrile to provide a dried [F- 18] fluoride ion in the Kryptofix ® structure.
- no-carrier-added [F- 18] CsF or [F- 18] tetraalkylammonium fluoride is used instead of [F- 18] KF/Kryptofix.
- Figure 1 shows the basic chemical reaction sequence for the preparation of five different phenyliodonium ylides.
- Figure 2 shows the reaction scheme for the preparation of substituted phenyliodonium ylide derivatives.
- Figure 3 shows the reaction of two different phenyliodonium ylides with acid.
- Figure 4 shows the products formed from the reaction of eight different phenyliodonium ylides with non-radioactive fluoride ion.
- Figure 5 shows the mechanism of the reaction of phenyliodonium ylide with fluoride ion.
- Figure 6 shows the reaction scheme for the synthesis of 6-[F-18]fluro-L-dopa.
- Figure 7 shows the reaction scheme for the synthesis of the oxazolidinone based iodonium ylide precursor for the preparation of 6-[F-18]fluro-L-dopa.
- Figure 8 shows the reaction scheme for the synthesis of the oxoimidazolidine and pyrazine based iodonium ylide precursors for the preparation of 6-[F- l8]fluro-L-dopa
- the new fluorination reaction developed in this invention utilizes the reaction of phenyliodonium ylides with no-carrier-added [F- 18] fluoride ion.
- Five different unsubstituted phenyliodonium ylides 3 - 7 shown in Figure 1 were selected for initial investigation.
- a general procedure for the synthesis of some of these ylides is known in the prior art (K. Schank and C. Lick, "Ozonolytic Fragmentation of Phenyliodonium Q- Diketonates: A Convenient Synthesis of Unsolvated v/c-Triketones.” Synthesis, pp 392- 395 (1983)).
- the phenyliododiacetoxy derivatives 2 and 9 were prepared by the periodate oxidation of the corresponding iodobenzenes in acetic acid medium as reported in the literature (P. Kazmierczak, L. Skulski and L. Kraszkiewicz, "Syntheses of (Diacetoxyiodo)arenes or Iodylarenes from Iodoarenes, with Sodium Periodate as the Oxidant.” Molecules, 6, pp 881-891 (2001) ).
- the iodonium ylides 3-5 were synthesized according to the procedure developed by Schank and Lick (K. Schank and C.
- the resulting suspension was poured into ice water and extracted with dichloromethane.
- the organic layer was dried over anhydrous sodium sulfate, filtered and evaporated in a rotary evaporator.
- the product (10a) was purified by silica gel column flash chromatography using 3 % methanol in dichloromethane as the eluent to provide the ylide as a white solid in 87 % yield.
- This product (10c) was prepared using the procedure set forth above in Example 1 using l-(diacetoxyiodo)-2-methoxybenzene (9c). A white solid was produced in 68 % yield.
- nucleophilic substitution reactions of the ylides 3-7 andl ⁇ a-h with fluoride, bromide, chloride etc in polar aprotic solvents led to regiospecific substitution of the nucleophiles on the aromatic ring instead of the dione ring.
- the nucleophile regiospecically substituted on the aromatic carbon atom that was carrying the positively charged iodine moiety.
- the iododione moieties in 3-7 and 10a-h likely act as the leaving group in this nucleophilic substitution reaction.
- the carbon atom on the aromatic ring carrying the positively charged iodine moiety has an electron deficiency and makes itself a more favorable point for the attack by the nucleophile to yield the fluoroaryl derivative ( Figure 5, Path A).
- Substitution of hydrogen on the aromatic ring to give the hydrocarbon derivatives i.e. benzene, toluene, mesitylene, anisole etc
- Such a radical pathway has previously been observed in the nucleophilic reaction of fluoride with the closely related iodonium salts (M.
- Kryptofix 222 ® is 4,7,13, 16,21,24-Hexaoxa-l,10-diazabicyclo[8.8.8]-hexacosane (Ci 8 H 36 N 2 O 6 ) with the following chemical structure:
- aqueous solution was evaporated at 120° C and the residue was further dried by azeotropic distillation with acetonitrile.
- Alternative encapsulating compounds can be used in place of Kryptofix 2.2.2 ® .
- dry no-carrier-added Cs 18 F or tetraalkylammonium [F-18]fluoride can be used in the place of K 18 F-Kryptof ⁇ x complex for the nucleophilic substitution reaction described above.
- Dry no-carrier-added Cs 18 F is prepared by treating Cs 2 CO 3 (1 mg) with [F- 18] fluoride ion prepared by the proton irradiation of [0-18] water and evaporating the water as an azeotrope with acetonitrile.
- Tetraalkylammonium [F- 18] fluoride (examples of preferred alkyl groups are methyl, ethyl, propyl, butyl, benzyl) is similarly prepared from the corresponding bicarbonate salt.
- a phenyliodonium ylide derivative (about 7 to 10 mg) was dissolved in dry DMF (1 mL) and added to the dried potassium [F-18]fluoride/Kryptofix complex or Cs 18 F or [F- 18] tetraalkylammonium fluoride as prepared above.
- the reaction vessel was then hermetically sealed with a glass or silicone stopper and heated to a temperature between 110° - 130° C for 10 - 15 min.
- the reaction mixture was cooled to room temperature and transferred to a silica gel chromatography column ( 12 X 1 cm ) where it was equilibrated with diethyl ether.
- the reaction mixture upon elution with 10 - 15 mL of ether, provided the [F- 18]fluorobenzene derivatives as evidenced by radioHPLC and radioTLC analyses.
- the reaction mixture can be processed using a Waters Corporation C- 18 Sep-Pak ® instead of the silica gel column. If the C- 18 Sep-Pak ® is used, the reaction mixture was diluted with 10 mL of water and passed through a C-18 Sep-Pak ® pre- equilibrated with methanol (5 mL) followed by water (10 mL). The Sep-Pak ® was flushed with water (10 mL) and the product was eluted out with 2 mL of methanol. The crude product recovered by either method was found to > 95 % radiochemical ⁇ pure. However, > 99 % radiochemical ⁇ and chemically pure product was obtained by semi- preparative HPLC purification of the crude reaction mixture using silica or C- 18 HPLC columns.
- Table 1 lists various phenyliodonium ylide precursors and the F- 18 labeled aryl derivatives described above obtained therefrom using this method along with the radiochemical yields.
- the ester 15 (38 mmol) was dissolved in dry DMF (60 mL) under argon and triethylamine (460 mmol) was added under stirring. A solution of di-tert-butyl dicarbonate (153 mmol) in dry DMF (40 mL) was then added drop-wise and the reaction mixture was stirred overnight at room temperature. The solution was then diluted with ethylacetate (60 mL) and washed with brine (2 X 100 mL) followed by water (3 X 100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated to produce the ester 16 as a white foam in 97 % yield.
- the dimethyldioxirane (DMDO) reagent was prepared as reported in the literature (R. W. Murray and M.Singh, "Synthesis of epoxides using dimethyldioxirane : trans-stilbene oxide.” Ore. Svn., 74, pp 91-96 (1998)).
- Acetone 40 mL was added to a solution of sodium bicarbonate (12.0 g) in water (50 mL).
- the white suspension formed was cooled in an ice bath to 0 0 C and solid oxone (24.0 g) was added over a period of 10-15 min with vigorous stirring.
- the DMDO reagent was added drop-wise to an ice cold solution of the tetraboc iodo derivative 18 (0.27 mmol) in acetone-acetic acid (4: 1) (2.0 mL) and the solution was stirred at O 0 C in an ice bath under argon for 1 h. The ice bath was then removed and the reaction mixture was stirred at room temperature for 3 h. The solvents were pumped off under high vacuum to leave the iodo-diacetoxy dopa analog 19 as white solid in 91% yield. The product was used in the next step without further purification.
- No-carrier-added [F-18]fluoride ion was produced by proton bombardment of [O- 18]water in a cyclotron.
- the aqueous [F-18]fluoride ion was treated with 1.0 mg of potassium carbonate and 10 mg of Kryptofix 2.2.2.
- the aqueous solution was evaporated at 120° C and the residue was dried by azeotropic distillation with acetonitrile.
- the iodonium ylide 20 (15-25 mg) was dissolved in dry DMF (1.0 mL) and added to the dried potassium [F-18]fluoride/Kryptof ⁇ x complex as prepared above. The reaction mixture was heated at 130° C for 15 min.
- the reaction mixture was cooled to room temperature and was diluted with 3 mL of ice water and passed through a C- 18 Sep-Pak pre- equilibrated with methanol (5 mL) followed by water (10 mL).
- the Sep-Pak was flushed with water (10 mL) and the F- 18 labeled intermediate product 21 was eluted out with 3 mL of chloroform.
- the chloroform was evaporated with a stream of nitrogen gas at 125 0 C.
- R 1 OCOOC(CH 3 ) 3 , OCH 3 ;
- F-18 labeled L-amino acids or D-amino acids having the formula:
- mineral acids such as HCI, HBr or HI
- Example 12 describes a procedure for preparing a specific compound in the manner described above
- Figure 7 shows of forst embodiment of the reaction scheme for the synthesis of the oxazolidinone based iodonium ylide precursor.
- the iodo derivative 17 (3.5 mmol) (prepared as shown in Figure 6) was dissolved in 40 mL of THF and cooled in an ice bath (0°C) and a solution of lithium hydroxide (7.0 mmol) in 12 mL of water was added dropwise under argon. The resulting mixture was stirred at 0 0 C for 4 h and then 2 h at room temperature. The reaction mixture was then neutralized with acetic acid to pH 5 and extracted with ethyl acetate.
- iodonium ylides having the formula
- R 2 OCH 2 Ph, OCOOC(CH 3 ) 3 , OCH 3 or
- R 1 OCH 2 Ph, OCOOC(CHs) 3 , OCH 3 ;
- R 2 H and
- F- 18 fluoride ion is derived from [F-18]KF/Kryptofix complex, [F- 18]CsF or quaternary ammonium fluoride, the quaternary ammonium groups selected from tetramethyl, yetraethyl, tetra n-butyl, and tetrabenzyl wherein
- R 2 H and
- resultant iodo compounds can be converted to F- 18 labeled L- amino acids having the formula
- Figure 8 shows the reaction scheme for the synthesis of specific oxoimidazolidine and pyrazine based iodonium ylide precursors
- 3,4-Dibenzyloxybenzaldehyde (27) (22.0 mmol) was suspended in 100 mL of anhydrous methanol and cooled to 0 0 C under argon. Sodium borohydride (33.0 mmol) was added in portions to the suspension and stirred for 1 h at the same temperature. The resulting solution was then stirred at room temperature overnight. The reaction mixture was evaporated to dryness and the residue was dissolved in ice-water and neutralized with HCl. The solution was then extracted with chloroform and the organic layer was washed successively with water, 10% NaHCO 3 solution in water and brine. The organic layer was dried over anhydrous Na 2 SO 4 , filtered and evaporated to dryness to provide pure 3,4- Dibenzyloxybenzyl alcohol (28) in 97.5 % yield.
- the dibenzyloxybenzyl alcohol 28 (21.44 mmol) and silver trifluoroacetate (21.44 mmol) were suspended in 100 mL of dry chloroform and stirred under argon.
- a solution of iodine (21.44mmol) in dry chloroform (50 mL) was added to the suspension dropwise at room temperature.
- the reaction mixture was then stirred for a further period of 2 h and filtered.
- the filtrate was washed with 20 % sodium thiosulfate solution in water.
- the organic layer was separated and dried over anhydrous Na 2 SO 4 . Filteration was followed by evaporation of the chloroform solution resulting in the pure iodo compound, 3,4-
- the carboxylate 31 was obtained using the general procedure reported in the literature [(D. Seebach, E. Dziadulewicz, L. Behrendt, S. Cantoreggi, R. Fitzi, "Synthesis of Nonproteinogenic (R)- or (S)-Amnio Acids Analogues of Phenylalanine, Isotopically Labelled and Cyclic Amino Acids from tert-Butyl 2-(tert-Butyl)-3-methyl-4-oxo-l- imidazolidinecarboxylate (Boc-BMI)." Liebigs Ann. Chem., pp 1215-1232 (1989)].
- the new reaction mixture was stirred for 3 h at the same temperature and then poured into a saturated solution of NH 4 CI.
- the product was extracted with EtOAc and the organic layer was washed with NaHCO 3 solution followed by brine.
- the organic phase was dried over anhydrous Na 2 SO 4 , filtered and evaporated to afford a yellow oil.
- the iodo oxoimidazolidine derivative 31 (0.22 mmol) was first oxidized with dimethyldioxirane in the presence of acetic acid as described above to afford the corresponding diacetoxy intermediate analog in 84 % yield.
- This diacetoxyiodo intermediate derivative can subsequently be converted to the the iodonium ylide 33 using the procedure given for the preparation of the analog 20.
- the diastereomeric product 32 was obtained by a reaction of the lithium salt of the chiral auxiliary (2R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine with the bromo derivative 30 using a modification of a procedure reported in the literature [U. Schollkopf, "Enantioselective Synthesis of Non-Proteinogenic Amino Acids via Metallated Bis-Lactim Ethers of 2,5-Diketopiperazines.” Tetrahedron. 39, pp 2085-2091 (1983)].
- (2R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (15.7 mmol) was dissolved in 10 mL of THF (freshly distilled from LiAlH 4 ). The light yellow solution was cooled to -78° C (dry ice/acetone bath) and stirred for 15 min under argon. A 2.5 M solution of n-butyl lithium (15.7 mmol) was added drop wise over a period of 10 min and the mixture was stirred for 20 min at -78° C. In a separate flask CuCN (7.86 mmol) was stirred with 10 mL of freshly distilled THF at room temperature for 10 min.
- the white suspension was then cooled to 0° C (ice bath) and stirred at that temperature for 20 min.
- the n-BuLi reaction mixture was then transferred to the white suspension of CuCN/THF under argon using a cannula.
- the resulting yellow suspension turned into a yellow solution within two minutes.
- the reaction mixture was then stirred at 0° C for 15 min and cooled to -78° C. After 15 min of stirring at -78° C, a solution of bromo derivative 30 (7.86 mmol) in 20 mL of freshly distilled THF was added drop wise. The color of the reaction mixture changed to greenish brown. After stirring for a further period of 2 h at - 78° C, the reaction mixture was warmed gradually to room temperature.
- 2,2-Dimethyl-4,6-dioxo-l,3-dioxane iodonium ylide derivative 34 This ylide derivative can also be prepared from the iodo product 32, first by oxidizing it with DMDO reagent in the presence of acetic acid to give the corresponding diacetoxyiodo product which upon reaction with 2,2-dimethyl-4,6-dioxo-l,3-dioxane as described above will provide the analog, 2,2-Dimethyl-4,6-dioxo-l,3-dioxane iodonium ylide derivative 34.
- the iodonium ylides 26, 33 and 34 can then be used as precursor materials for the preparation of 6-[F-18]fluoro-L-dopa in the manner described above. They can then be reacted with [F- 18] fluoride ion as described above. The F- 18 labeled intermediates upon acid hydrolysis will yield 6-[F-18]fluoro-L-dopa. Further, the F-18 fluorinated D- and L- chiral amino acids can be prepared by starting with the appropriate D- and L- chiral precursors.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Abstract
Phenyliodonium ylide derivatives substituted with electron donating as well as electron withdrawing groups on the aromatic ring are shown for use as precursors in aromatic nucleophilic substitution reactions. The iodonium ylide group is substituted by nucleophiles such as halide ions to provide the corresponding haloaryl derivatives. No- carrier-added [F-18]fluoride ion exclusively substitutes the iodonium ylide moiety in these derivatives and provides high specific activity F- 18 labeled fluoro derivatives. Protected L-dopa-6-iodonium ylide derivative have been synthesized as a precursors for the preparation of no-carrier-added 6-[F- 18]fluoro-L-dopa. The iodonium ylide group in this L-dopa.derivative is nucleophilically substituted by no-carrier-added [F-18]fluoride ion to provide a [F-18]fluoro intermediates which upon acid hydrolysis yielded 6-[F- 18]fluoro-L-dopa.
Description
No-Carrier- Added Nucleophilic [F- 18] Fluorination of Aromatic Compounds
BACKGROUND
[0001] Incorporation of positron emitting fluorine-18 (half-life=110 min) into aromatic ring systems plays a very important role in , the development of novel biomarkers for utilization in Positron Emission Tomography (PET). Two major pathways are commonly used for this process, namely, electrophilic and nucleophilic fluorine substitution reactions.
[0002] Electrophilic fluorination reactions can only provide products with low specific activities (ca 1-5 Ci/mmol) because of the unavoidable addition of non-radioactive elemental fluorine (often called carrier fluorine) during the current production techniques for F- 18 labeled fluorine. The combination of labeled fluorine and carrier fluorine is referred to as [ F] F2. A typical example of electrophilic radiofluorination can be summarized by the following reaction:
Where R = electron withdrawing groups (e.g. CHO, COOEt, CN, NO2 etc) or electron donating groups (e.g. CH3, OCH3 etc.)
[0003] Low specific activity biomarkers prepared by electrophilic aromatic radiofluorination reactions with [F-18]fluorine and reagents derived from it are generally useful for monitoring enzyme-mediated processes (e.g., aromatic amino acid decarboxylase dependent transformation). However, they are unsuitable for investigation of biochemical processes such as receptor systems or enzyme inhibition.
[0004] Nucleophilic radiofluorination of aromatic rings, on the other hand, provides products with high specific activity (ca 1,000 - 10,000 Ci/mmol). Unlike molecular [F- 18]fluorine which is obtained in 0.3 - 0.7 Ci levels, high specific activity [F-18]fluoride ion, which is the fluorinating agent for nucleophilic substitution reactions, is more conveniently prepared in large quantities (1 - 10 Ci). Facile displacement of certain leaving groups (e.g. nitro and quaternary ammonium moiety) in aromatic systems activated by electron withdrawing substituents (e.g. CHO, COCH3, NO2, CN, COOCH3) by high specific activity [F-18]fluoride ion is well documented and can be depicted as follows:
Where R = electron withdrawing groups (e.g. CHO, COOEt, CN, NO2 etc) located at ortho or para position with respect to the group X, and X = NO2 orθ N(CH3)3
[0005] Simple deactivated aromatic rings, such as the example cited above, provide [F- 18]fluorinated products in good radiochemical yields (30 - 80%). However, as the complexity of the aromatic ring system increases (which is the case with almost all the useful biomarkers) the radiochemical yields obtained by this reaction drops drastically. Further, aromatic compounds lacking electron withdrawing/deactivating substituents (i.e. CHO, CN, NO2 etc) fail to undergo this reaction. Two different routes have been formulated for aromatic nucleophilic fluorination reactions for rings that carry deactivating substituents (e.g. CHO, NO2, CN etc) as well as groups that are electron donating in nature (e.g. CH3, OCH3). The first reaction involves an acid catalyzed thermal decomposition of phenyl triazenes bearing electron donating or electron withdrawing groups on the aromatic ring as shown below:
H*C-N'
18F
H@
18p Q
R R
Where R = electron donating groups (e.g. CH3, OCH3 etc) or electron withdrawing (CHO, NO2, CN) group substituted at ortho, meta, para position with respect to the triazene moiety.
[0006] The second approach for the nucleophilic fluorination of aryl derivatives substituted with electron donating or electron withdrawing groups involves utilization of iodonium salts as depicted below:
R1 and R2 = electron donating (e.g. CH3, OCH3 etc) or electron withdrawing (CHO, NO2 etc) groups located at ortho, meta or para positions with respect to the iodonium moiety.
X© = triflate, tosylate or brorride.
[0007] While the radiochemical yield for this reaction is generally good with simple
18 substrates, the radiolabeled fluorine (i.e. F) can end up on either of the phenyl rings. Thus, essentially this reaction provides a mixture of two F-18 labeled products; usually one of them is the desired product while the second one is an unwanted product. The percent distribution of the radiolabeled Huorinated products depends upon the electron donating/electron withdrawing nature of the substituent (i.e. Ri and R2) on the phenyl rings. In these iodonium salts, the phenyl ring carrying an electron withdrawing group is invariably radiofluorinated in higher yields than its counterpart phenyl ring substituted
with an electron donating group. To obviate this shortcoming a new class of iodonium salt having a thiophene ring system has been advanced. Reaction of this thiophene
X® = triflate
iodonium salt with no carrier added F- 18 fluoride ion has been reported to yield [F-18]fluorobenzene as the single radiolabeled product (T.L. Ross, J. Ermert, C. Hocke and H.H. Coenen, "Nucleophilic ' 8F-Fl uorination of Heteroaromatic Iodonium Salts with No-Carrier-Added [18F]Fluoride." J.Am. Chem. Soc, 129, pp 8018-8025 (2007)). However, later careful analysis of this reaction mixture has revealed that both [F- 18]fluorobenzene and 2-[F-18]fluorothiophene were produced (M. Carroll, C. Jones and S. -L. Tang, "Fluoridation of 2-thienyliodonium salts". J. Label. Compd. Radiopharm., 50, pp 450-451 (2007)).
[0008] Thus, there is a great need for fluorination reactions and particularly for nucleophilic aromatic fluorination reaction conditions that are suitable for the preparation of F-18 labeled biomarkers having a variety of substituents, including electron donating groups. Using such reactions will make many different biomarkers easily accessible and will facilitate development and use of molecular imaging probes for PET. It is also anticipated that similar reactions with various nucleophiles would expand the utility of the approach to a multitude of labeled and unlabeled molecules.
SUMMARY
[0009] A novel aromatic nucleophilic halogenation reaction which proceeds without the addition or inclusion of an ion carrier is described. In particular, a fluorination reaction which proceeds without the addition or inclusion of an [F-18] fluoride ion carrier is set
forth. In a preferred procedure this "no-carrier-added" [F- 18] fluoride ion is reacted with a phenyliodonium ylide derivative, with the fluoride ion nucleophilically substituting the iodonium ylide group on the aromatic ring, resulting in regiospecific F- 18 labeled aromatic compounds. The no-carrier-added [F- 18] fluoride ion is produced by proton irradiation of [0-18] water using a cyclotron. The [F- 18] fluoride ion is then treated with potassium carbonate and a Kryptofix® ligand and the aqueous solution is evaporated. The residue is further dried using azeotropic distillation with acetonitrile to provide a dried [F- 18] fluoride ion in the Kryptofix® structure. Alternatively, no-carrier-added [F- 18] CsF or [F- 18] tetraalkylammonium fluoride is used instead of [F- 18] KF/Kryptofix. The phenyliodonium ylide compound dissolved in DMF is then reacted with the dried [F- 18]fluoride ion to form the [F-18] fluoroaryl derivative which is isolated using silica gel column chromatography. These [F-18] fluorinated aromatic compounds can have applications in Positron Emission Tomography (PET).
BRIEF DESCRIPTION OF DRAWINGS
[0010] Figure 1 shows the basic chemical reaction sequence for the preparation of five different phenyliodonium ylides.
[0011] Figure 2 shows the reaction scheme for the preparation of substituted phenyliodonium ylide derivatives.
[0012] Figure 3 shows the reaction of two different phenyliodonium ylides with acid.
[0013] Figure 4 shows the products formed from the reaction of eight different phenyliodonium ylides with non-radioactive fluoride ion.
[0014] Figure 5 shows the mechanism of the reaction of phenyliodonium ylide with fluoride ion.
[0015] Figure 6 shows the reaction scheme for the synthesis of 6-[F-18]fluro-L-dopa.
[0016] Figure 7 shows the reaction scheme for the synthesis of the oxazolidinone based iodonium ylide precursor for the preparation of 6-[F-18]fluro-L-dopa.
[0017] Figure 8 shows the reaction scheme for the synthesis of the oxoimidazolidine and pyrazine based iodonium ylide precursors for the preparation of 6-[F- l8]fluro-L-dopa
DETAILED DESCRIPTION
[0018] The new fluorination reaction developed in this invention utilizes the reaction of phenyliodonium ylides with no-carrier-added [F- 18] fluoride ion. Five different unsubstituted phenyliodonium ylides 3 - 7 shown in Figure 1 were selected for initial investigation. A general procedure for the synthesis of some of these ylides is known in the prior art (K. Schank and C. Lick, "Ozonolytic Fragmentation of Phenyliodonium Q- Diketonates: A Convenient Synthesis of Unsolvated v/c-Triketones." Synthesis, pp 392- 395 (1983)). These derivatives were synthesized by oxidizing iodobenzene (1) with sodium periodate in the presence of sodium acetate and acetic anhydride in acetic acid medium to give diacetoxy iodobenzene (2) which upon reaction with cyclic 1,3-dione analogs provided the corresponding phenyliodonium ylides 3 - 7 (Figure 1).
[0019] Eight substituted phenyliodonium ylides were also similarly synthesized as shown in Figure 2.
[0020] The phenyliododiacetoxy derivatives 2 and 9 were prepared by the periodate oxidation of the corresponding iodobenzenes in acetic acid medium as reported in the literature (P. Kazmierczak, L. Skulski and L. Kraszkiewicz, "Syntheses of (Diacetoxyiodo)arenes or Iodylarenes from Iodoarenes, with Sodium Periodate as the Oxidant." Molecules, 6, pp 881-891 (2001) ). The iodonium ylides 3-5 were synthesized according to the procedure developed by Schank and Lick (K. Schank and C. Lick, "Ozonolytic Fragmentation of Phenyliodonium D-Diketonates: A Convenient Synthesis of Unsolvated vic-Triketones." Synthesis, pp 392-395 (1983)) while the compounds 6 and 7 were prepared as reported in the literature (T. Kappe, G. Korbuly, and W. Stadlbauer, "Ylide von Heterocyclen, II. Iodonium- und Pyridinium- Ylide von Malonylheterocyclen." Chem. Ber.. I l l, pp 3857-3866 (1978)). The molecular weight of the compounds produced was determined using matrix-assisted laser desorption ionization mass spectroscopy (MS-MALDI).
[0021] The substituted phenyiodonium ylides 10a - d and 1Of - h (Figure 2) are heretofore unreported in the literature and were newly synthesized for this investigation. Typical experimental procedure used for their synthesis is summarized below:
[0022] EXAMPLE 1 - 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(4-methylphenyl)iodonium ylide (10a)
[0023] A solution of l-(diacetoxyiodo)-4-methylbenzene (9a) (2 mmol) in ethanol (8 mL) was added to a solution of 2,2-dimethyl-l,3-dioxane-4,6-dione (2 mmol) in 10 % sodium carbonate in water (6 mL). The mixture was stirred at room temperature for 4 h.
The resulting suspension was poured into ice water and extracted with dichloromethane.
The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated in a rotary evaporator. The product (10a) was purified by silica gel column flash chromatography using 3 % methanol in dichloromethane as the eluent to provide the ylide as a white solid in 87 % yield.
1H NMR (CDCl3): 0 7.81 (d, 2H, ArH), 7.24 (d, 2H, ArH), 2.43 (s, 3H, CH3), 1.72 (s, 3H,
CH3), 1.62 (s, 3H, CH3).
MS (MALDI): Calcd for Ci3H13O4I (M+): 359.99; Found: 382.99 (M++Na).
[0024] EXAMPLE 2 -2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(2,4,6-trimethylphenyl) iodonium ylide (10b)
[0025] The synthesis of this ylide (10b) was carried out according to the procedure set forth in Example 1 using the diacetoxy derivative 9b. The product was a white solid obtained in 92 % yield.
1H NMR (CDCl3): D 7.26 (d, 2H, ArH), 2.79 (s, 6H, 2 ArCH3), 2.32 (s, 3H, ArCH3), 1.62
(s, 6H, 2 CH3);
MS (MALDI): Calcd for Ci5HnO4I (M+): 388.02; Found: 410.67 (M++Na).
[0026] EXAMPLE 3 - 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(2-methoxyphenyl) iodonium ylide (10c)
[0027] This product (10c) was prepared using the procedure set forth above in Example 1 using l-(diacetoxyiodo)-2-methoxybenzene (9c). A white solid was produced in 68 % yield.
1H NMR (CDCl3): □ 7.51-7.00 (m, 4H, ArH), 4.01 (s, 3H, OCH3), 1.82 (s, 3H, CH3), 1.58
(s, 3H, CH3).
MS (MALDI): Calcd for Ci3Hi3O5I (M+): 375.98; Found: 398.98 (M++Na).
[0028] EXAMPLE 4 - 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(3-methoxyphenyl) iodonium ylide (1Od)
[0029] The diactoxyiodobenzene analog 9d was used for the preparation of the ylide
(1Od) using the method described above in Example 1. The product was obtained as a white solid in 84 % yield.
1H NMR (CDCl3): D 7.43 (m, 2H, ArH), 7.32 (m, IH, ArH), 7.09 (dd, IH, ArH), 3.83 (s,
3H, OCH3), 1.72 (s, 6H, 2CH3).
MS (MALDI): Calcd for C13H13O5I (M+): 375.98; Found: 398.60 (M++Na).
[0030] EXAMPLE 5 - 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(4-methoxyphenyl) iodonium ylide (1Oe)
[0031] Using the procedure described above starting with l-(diacetoxyiodo)-4- methoxybenzene (9e), the ylide (1Oe) was obtained as a white solid in 79 % yield. 1H NMR (CDCl3): 0 7.50 (s, 2H, ArH), 7.26 (s, 2H, ArH), 3.90 (s, 3H, OCH3), 1.57 (s, 6H, 2CH3)). MS (MALDI): Calcd for Ci3H13O5I (M+): 375.98; Found: 398.98 (M++Na).
[0032] This product (1Oe) was found to be identical to the same ylide obtained by a previously published procedure (O. Neilands and B. Karele, "Iodonium derivatives of D- diketones. XVII. Aryiodonium derivatives of isopropylidene malonate." J.Org.Chem.. USSR (Engl. TransU. 7, pp 1674-1677 (1971)).
[0033] EXAMPLE 6 - 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(4-bromophenyl)iodonium ylide (1Of)
[0034] Using the procedure of Example 1 and l-bromo-4-(diacetoxyiodo)benzene (9f) as a starting material the ylide (1Of) was obtained as a pale yellow solid in 69 % yield! 1H NMR (CDCl3): D 7.80 (d, 2H, ArH), 7.56 (d, 2H, ArH), 1.73 (s, 6H, 2CH3)). MS (MALDI): Calcd for C12Hi0BrO4I (M+): 423.88; Found: 446.51 (M++Na).
[0035] EXAMPLE 7 - 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(4-chlorophenyl)iodonium ylide (1Og)
[0036] Using the procedure given above in Example 1 and diacetoxyiodobenzene derivative 9g the ylide (1Og) was produced as a white solid in 71 % yield.
1H NMR (CDCl3): D 7.88 (d, 2H, ArH), 7.44 (d, 2H, ArH), 1.73 (s, 6H, CH3), 1.60 (s, 3H,
CH3).
MS (MALDI): Calcd for Ci2H,oClI04 (M+): 379.93; Found: 402.55 (M++Na).
[0037] EXAMPLE 8 - 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-(4-nitrophenyl)iodonium ylide (1Oh)
[0038] Using the procedure of Example 1 and starting with the diacetoxy nitrophenyl derivative 9h, the ylide (1Oh) was obtained in 74 % yield. 1H NMR (CDCl3): D 8.28 (d, 2H, ArH), 8.08 (d, 2H, ArH), 1.73 (s, 6H, 2 CH3). MS (MALDI): Calcd for C12H10INO6 (M+): 390.96; Found: 413.60 (M++Na).
[0039] Nucleophilic Substitution Reactions with the Phenyliodonium Ylides
[0040] The reactivity of phenyliodonium ylides with simple nucleophiles such as halide ions in anhydrous media has not yet been reported in the literature. However, the reactivity of phenyliodonium ylides with Bronsted acids such as HCl and HBr and organic acids such as acetic acid has been demonstrated (O. Neilands and B. Karele, "Iodonium derivatives of D-diketones. XVII. Aryiodonium derivatives of isopropylidene malonate." J.Qrg.Chem.. USSR (Engl. Trans!.), 7, pp 1674-1677 (1971); T. Kappe, G. Korbuly, and W. Stadlbauer, "Ylide von Heterocyclen, II. Iodonium- und Pyridinium- Ylide von Malonylheterocyclen." Chem. Ber., JJJ., pp 3857-3866 (1978); N.S. Habib, "Ylides of Heterocycles. VII. [I]. I-, N-, P- and S- Ylides of Pyrimidones." J. Heterocyclic Chem., 21, pp 385-388 (1984); E. Pongratz and T. Kappe, "Ylide von Heterocyclen. VIII Reaktionen von Iodonium- Yliden mit Sauren." Monatsh. Chem., 115, pp 231-242 (1984)). A typical example of such a reaction is summarized in Figure 3.
[0041] The reaction of the ylides 6 and 7, for example, with acids like HCl and HBr as well as acetic acid and trifluoroacetic acid first leads to the protonation of one of the keto groups followed by the nucleophilic attack of the conjugate base of the acid on the heterocyclic ring to give the products shown in Figure 3 identified as 11 and 12 (E. Pongratz and T. Kappe, "Ylide von Heterocyclen. VIII Reaktionen von Iodonium-Yliden mit Sauren." Monatsh. Chem., 115, pp 231-242 (1984)). Thus, iodobenzene (1) acts as a facile leaving group in all these reactions and the nucleophiles (i.e. the conjugate base of the acids) exclusively attack the heterocyclic ring system to form products 11 and 12.
[0042] In sharp contrast to the reaction of the iodonium ylides with acids, we found nucleophilic substitution reactions of the ylides 3-7 andlθa-h with fluoride, bromide, chloride etc in polar aprotic solvents led to regiospecific substitution of the nucleophiles on the aromatic ring instead of the dione ring. The nucleophile regiospecically substituted on the aromatic carbon atom that was carrying the positively charged iodine moiety.
Thus, the iododione moieties in 3-7 and 10a-h likely act as the leaving group in this nucleophilic substitution reaction.
[0043] Shown herein, for the first time is the reaction of halide ions (fluoride, chloride and bromide) with the iodonium ylides 3-7 and 10a-h in non-aqueous aprotic solvents such as acetonitrile, tetrahydrofuran, dimethylsulfoxide and dimethylacetamide and dimethylformamide. Typical experimental conditions used for the fluoride ion reaction are given below:
[0044] EXAMPLE 9 -
[0045] A solution of Kryptofix 2.2.2 (40 Ornol) in acetonitrile ( 1 mL) was added to a solution of KF (25 Qmol) in water (0.1 mL). The solvents were evaporated at 120° C and the residue was dried by azeotropic distillation with acetonitrile (3 X 1 mL). A solution of the phenyliodonium ylide precursor in dry dimethylformamide (1.0 mL) was added to the dried KF-Kryptofix complex and the reaction vessel was hermetically sealed. The reaction mixture was heated at 1300C for 15 min. The reaction mixture was cooled to room temperature and processed with a silica gel chromatography column (12 X 1 cm). The products of the reaction were eluted off the column with diethyl ether (20 mL) and analyzed by GC/MS (30 m X 0.25 mm J&W Scientific DB-5MS capillary column; Varian Saturn 2000 mass spectrometer) and by analytical HPLC (Phenomenex Luna Cl 8 column, 5μ particle size, 250 X 4.6 mm; eluent : methanol/water = 75/25; flow rate : 1 mL/min; UV detection at 254 nm).
[0046] The products observed by GC/MS and analytical HPLC in these reactions are summarized in Figure 4.
[0047] In each of these reactions with the fluoride ion, only three major aromatic products were observed — substitution of the nucleophile on the aromatic ring to yield a fluoroaryl derivative, substitution of hydrogen on the aromatic ring to give the arene and formation of an iodoaryl analog. GC/MS analysis conclusively proved the identity of
these products. Analytical HPLC data supported the GC/MS data. The GC/MS analysis showed that the nucleophile (i.e. fluoride) did not substitute on the dione moiety to yield l-fluoro-2,2-dimethyl-l,3-dioxane-4,6-dione (13) (Figure 5, Path B) but instead the fluoride substituted regiospecifically on the phenyl ring on the ipso carbon. This observation can be rationalized by the presence of a delocalized negative charge distributed over the dione part of the dioxane ring system which would repel the nucleophile (i.e. fluoride ion) also carrying a negative charge.
[0048] On the other hand, the carbon atom on the aromatic ring carrying the positively charged iodine moiety has an electron deficiency and makes itself a more favorable point for the attack by the nucleophile to yield the fluoroaryl derivative (Figure 5, Path A). Substitution of hydrogen on the aromatic ring to give the hydrocarbon derivatives (i.e. benzene, toluene, mesitylene, anisole etc) strongly indicate involvement of a competing radical pathway for this nucleophilic substitution reaction and abstraction of hydrogen from the solvent. Such a radical pathway has previously been observed in the nucleophilic reaction of fluoride with the closely related iodonium salts (M. Van Der Puy, "Conversion of Diaryiodonium Salts to Aryl Fluorides." J. Flourine Chem. 21. pp 385-392 (1982)). Thus, when the trimethyl substituted iodonium ylide (10b) reaction was conducted in a deuterated solvent (e.g. DMF-d7) GC/MS analysis showed the presence of deutereomesitylene (Figure 4) in the product mixture indicating a radical channel competing with the nucleophilic substitution reaction.
[0049] EXAMPLE 10 -
[0050] Conditions for a radiolabeling reaction are as follows: No-carrier-added [F- 18]fluoride ion was produced by proton bombardment of [O- 18] water in a cyclotron target body. The only fluorine moiety produced is the [F-18]ion. The aqueous [F- 18]fluoride ion was treated with 1.0 mg of potassium carbonate and 10 mg of Kryptofix 2.2.2.® compound to form an aqueous solution. Kryptofix 2.2.2® compound is one example of a family of synthetic bi- and polycyclic multidentate ligands capable of encapsulating a variety of cations, referred to generically as cryptands. Kryptofix 222® is
4,7,13, 16,21,24-Hexaoxa-l,10-diazabicyclo[8.8.8]-hexacosane (Ci8H36N2O6) with the following chemical structure:
The aqueous solution was evaporated at 120° C and the residue was further dried by azeotropic distillation with acetonitrile. Alternative encapsulating compounds can be used in place of Kryptofix 2.2.2®. For example, dry no-carrier-added Cs18F or tetraalkylammonium [F-18]fluoride can be used in the place of K18F-Kryptofϊx complex for the nucleophilic substitution reaction described above. Dry no-carrier-added Cs18F is prepared by treating Cs2CO3 (1 mg) with [F- 18] fluoride ion prepared by the proton irradiation of [0-18] water and evaporating the water as an azeotrope with acetonitrile. Tetraalkylammonium [F- 18] fluoride (examples of preferred alkyl groups are methyl, ethyl, propyl, butyl, benzyl) is similarly prepared from the corresponding bicarbonate salt.
[0051] A phenyliodonium ylide derivative (about 7 to 10 mg) was dissolved in dry DMF (1 mL) and added to the dried potassium [F-18]fluoride/Kryptofix complex or Cs18F or [F- 18] tetraalkylammonium fluoride as prepared above. The reaction vessel was then hermetically sealed with a glass or silicone stopper and heated to a temperature between 110° - 130° C for 10 - 15 min. The reaction mixture was cooled to room temperature and transferred to a silica gel chromatography column ( 12 X 1 cm ) where it was equilibrated with diethyl ether. The column, upon elution with 10 - 15 mL of ether, provided the [F- 18]fluorobenzene derivatives as evidenced by radioHPLC and radioTLC analyses. Alternatively, the reaction mixture can be processed using a Waters Corporation C- 18 Sep-Pak® instead of the silica gel column. If the C- 18 Sep-Pak® is used, the reaction mixture was diluted with 10 mL of water and passed through a C-18 Sep-Pak® pre- equilibrated with methanol (5 mL) followed by water (10 mL). The Sep-Pak® was
flushed with water (10 mL) and the product was eluted out with 2 mL of methanol. The crude product recovered by either method was found to > 95 % radiochemical^ pure. However, > 99 % radiochemical^ and chemically pure product was obtained by semi- preparative HPLC purification of the crude reaction mixture using silica or C- 18 HPLC columns.
[0052] Table 1 lists various phenyliodonium ylide precursors and the F- 18 labeled aryl derivatives described above obtained therefrom using this method along with the radiochemical yields.
TABLE 1 Nucleophilic Fluorination of Phenyl Iodonium Ylides with No-Carrier- Added
[ rll8βF]Fluoride Ion
[0053] The iodonium ylides 10a-h were also successfully reacted with no-carrier-added [F-18]fluoride ion as described in the above procedure and the radiochemical yields obtained for various [F-18]fluoroaryl derivatives are listed in Table 2.
TABLE 2
Nucleophilic Fluorination of Substituted Phenyl Iodonium Ylides with No-Carrier- Added [18F]Fluoride Ion
[0054] The versatility of the fluorination reaction described herein is further demonstrated in Example 11 and Figure 6 wherein 6-[F-18]fluoro-L-dopa (21) was synthesized. The F- 18 labeled amino acid (L-dopa) 21 is a very useful PET imaging agent for mapping dopamine related brain disorders as well as brain tumors and is the PET biomarker of choice for the diagnosis of Parkinson's disease.
[0055] EXAMPLE 11 -
[0056] The synthesis of the intermediate compounds and the preparation of the [F- 18] fluoro-L-dopa is as follows:
[0057] a) 3,4-Dihydroxy-L-phenylalanine ethyl ester (15)
Standard Fisher esterfication of L-dopa (14) (0.13 mol) in anhydrous ethanol (500 mL) with dry HCl gas provided the ester 15 in quantitative yield.
[0058] b) N-(tert-butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-L-phenylalanine ethyl ester (16)
The ester 15 (38 mmol) was dissolved in dry DMF (60 mL) under argon and triethylamine (460 mmol) was added under stirring. A solution of di-tert-butyl dicarbonate (153 mmol) in dry DMF (40 mL) was then added drop-wise and the reaction mixture was stirred overnight at room temperature. The solution was then diluted with ethylacetate (60 mL) and washed with brine (2 X 100 mL) followed by water (3 X 100 mL). The organic layer was dried over anhydrous sodium sulfate, filtered and evaporated to produce the ester 16 as a white foam in 97 % yield.
(1H NMR (CDCl3): D 7.18 (d, IH, ArH), 7.03 (s, IH, ArH), 7.00 (d, IH, ArH), 5.03
(broad d, IH, NH), 4.54 (q, IH), 4.19-4.11 (m, 2H), 3.09 (m, 2H), 1.54 (s, 18H), 1.43 (s,
9H), 1.22 (t, 3H);
(13C NMR (CDCl3): Q 171.50, 155.08, 150.71, 150.60, 142.29, 141.45, 134.80, 127.19,
124.00, 122.97, 116.41, 83.74, 79.98, 61.54, 60.39, 54.24, 37.55, 21.05, 14.19, 14.08;
MS (MALDI): Calcd for C26H39NOi0 (M+): 525.26; Found: 548.07 (M++Na)).
[0059] c) N-(tert-butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-iodo-L- phenylalanine ethyl ester (17)
Iodine (7.4 mmol) and bis(trifluoroacetoxy)iodobenzene (8.16 mmol) were added to a solution of the tri-boc protected dopa ester analog 16 (5.7 mmol) in anhydrous dichloromethane (60 mL) under argon. The reaction mixture was stirred at room temperature for 40 min and then quenched with a saturated solution of sodium thiosulfate. The organic layer was washed with water (3 X 10 mL), dried with anhydrous sodium sulfate, filtered and evaporated in a rotary evaporator. The product was purified by silica gel column chromatography using 15-20% ethyl acetate in hexane as the mobile phase to give the iodo analog 17 as white foam in 77% yield.
(1H NMR (CDCl3): D 7.74 (s, IH, ArH), 7.14 (s, IH, ArH), 5.08 (broad d, IH, NH), 4.59 (q, IH), 4.22-4.12 (m, 2H), 3.20 (m, 2H), 1.55 (s, 18H), 1.42 (s, 9H), 1.22 (t, 3H);
13C NMR (CDCl3): Q 171.61, 154.97, 150.25, 150.19, 142.57, 141.50, 138.13, 133.50,
124.24, 95.47, 84.19, 84.07, 80.03, 61.69, 60.40, 53.47, 42.56, 28.27, 27.59, 21.07,
14.03;
MS (MALDI): Calcd for C26H38NOi0I (M+): 651.15; Found: 674.00 (M++Na).
[0060] d) N-di(tert-butoxycarbony l)-3 ,4-di(tert-butoxycarbonyloxy)-6-iodo-L- phenylalanine ethyl ester (18)
The iodo analog 17 (0.76 mmol) was dissolved in dry THF (5 mL) under argon and 4-
(dimethylamino)pyridine (3.8 mmol) and di-tert-butyldicarbonate (2.85 mmol) were added. The reaction mixture was stirred at room temperature overnight. The resulting yellow solution was diluted with ethyl acetate and washed with water (3 X 30 mL). The ethyl acetate layer was dried with anhydrous sodium sulfate, filtered and evaporated to produce a semi-solid residue. This crude product upon purification by flash chromatography over silica gel with 15-20% ethyl acetate in hexane as eluent gave the tetra boc derivative 18 in 74% yield as white foam.
(1H NMR (CDCl3): D 7.68 (s, IH, ArH), 7.06 (s, IH, ArH), 5.24 (q, IH), 4.24-4.08 (m,
2H), 3.20 (m, 2H), 1.52 (s, 18H), 1.38 (s, 18H), 1.20 (t, 3H);
13C NMR (CDCl3): D 169.87, 151.76, 150.16, 150.11, 142.48, 141.33, 139.13, 133.24,
124.86, 95.41, 84.07, 83.87, 83.18, 61.53, 57.39, 40.15, 27.86, 27.57, 14.16;
MS (MALDI): Calcd for C31H46NO12I (M+): 751.21; Found: 774.07 (M++Na)).
[0061] e) N-di-(tert-butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6- (diacetoxy)iodo-L-phenylalanine ethyl ester (19)
The dimethyldioxirane (DMDO) reagent was prepared as reported in the literature (R. W. Murray and M.Singh, "Synthesis of epoxides using dimethyldioxirane : trans-stilbene oxide." Ore. Svn., 74, pp 91-96 (1998)). Acetone (40 mL) was added to a solution of sodium bicarbonate (12.0 g) in water (50 mL). The white suspension formed was cooled in an ice bath to 00C and solid oxone (24.0 g) was added over a period of 10-15 min with vigorous stirring. The mixture was stirred at 0° C for an additional period of 5 min and then distilled at room temperature for 45 - 60 min under vacuum (100 torr). A pale
yellow distillate of DMDO (-30 mL) in acetone, collected in a flask cooled in a -78° C bath, was dried with anhydrous sodium sulfate and filtered. The pale yellow filtrate containing DMDO was used immediately in the next step.
[0062] The DMDO reagent was added drop-wise to an ice cold solution of the tetraboc iodo derivative 18 (0.27 mmol) in acetone-acetic acid (4: 1) (2.0 mL) and the solution was stirred at O0C in an ice bath under argon for 1 h. The ice bath was then removed and the reaction mixture was stirred at room temperature for 3 h. The solvents were pumped off under high vacuum to leave the iodo-diacetoxy dopa analog 19 as white solid in 91% yield. The product was used in the next step without further purification.
(1H NMR (CDCl3): D 8.11 (s, IH, ArH), 7.45 (s, IH, ArH), 5.24 (q, IH), 4.25-4.15 (m,
2H), 3.66 (m, 2H), 2.09 (s, 6H), 1.54 (s, 18H), 1.41 (s, 18H), 1.26 (t, 3H);
13C NMR (CDCl3): D 176.87, 176.67, 169.57, 151.71, 149.91, 149.84, 149.76, 145.31,
141.88, 139.64, 132.41, 125.22, 121.60, 84.62, 84.57, 83.56, 61.81, 59.14, 38.79, 27.99,
27.87, 27.57, 20.74, 20.33, 14.12;
MS (MALDI): Calcd for C35H52NO16I (M+): 869.23; Found: 892.00 (M++Na)).
[0063] 0 2,2-Dimethyl-4,6-dioxo- l,3-dioxan-5-[N-di(tert-butoxycarbonyl)-3,4-di-
(tert-butoxycarbonyloxy)-L-phenylalanine ethyl ester-6-iodonium] ylide (20)
2,2-dimethyl-4,6-dioxo-l,3-dioxane (0.27 mmol) was added under argon to a solution of the iododiacetoxy dopa analog 19 (0.27 mmol) in anhydrous dichloromethane (6 mL) and the solution was stirred at room temperature overnight. The solvent was then evaporated and the product purified by flash chromatography on silica gel using 60-70% ethyl acetate in hexane as eluent to give the iodonium ylide 20 in 68% yield.
(1H NMR (CDCl3): D 7.99 (s, IH, ArH), 7.39 (s, IH, ArH), 5.31 (q, IH), 4.25-4.18 (m,
2H), 3.93-3.29 (m, 2H), 1.68 (s, 6H), 1.56 (s, 18H), 1.53 (s, 18H), 1.26 (t, 3H);
13C NMR (CDCl3): Q 170.36, 164.02, 151.76, 149.73, 149.59, 145.72, 145.42, 138.05,
129.80, 125.30, 118.04, 104.34, 84.69, 84.60, 84.25, 62.18, 59.57, 59.07, 39.47, 27.96,
27.81, 27.49, 25.96, 13.96;
MS (MALDI): Calcd for C37H53NO16I (M+): 894.24; Found: 916.07 (M++Na)).
[0064] g) 6-[F- 18]fluoro-L-dopa (21)
No-carrier-added [F-18]fluoride ion was produced by proton bombardment of [O- 18]water in a cyclotron. The aqueous [F-18]fluoride ion was treated with 1.0 mg of potassium carbonate and 10 mg of Kryptofix 2.2.2. The aqueous solution was evaporated at 120° C and the residue was dried by azeotropic distillation with acetonitrile. The iodonium ylide 20 (15-25 mg) was dissolved in dry DMF (1.0 mL) and added to the dried potassium [F-18]fluoride/Kryptofϊx complex as prepared above. The reaction mixture was heated at 130° C for 15 min. The reaction mixture was cooled to room temperature and was diluted with 3 mL of ice water and passed through a C- 18 Sep-Pak pre- equilibrated with methanol (5 mL) followed by water (10 mL). The Sep-Pak was flushed with water (10 mL) and the F- 18 labeled intermediate product 21 was eluted out with 3 mL of chloroform. The chloroform was evaporated with a stream of nitrogen gas at 1250C.
[0065] h) Purified 6-[F- 18] fluoro-L-dopa (22)
The residue after evaporation of the chlorofoam was subjected to acid hydrolysis with 37 % HCl at 125°C for 15 min. The acidic solution was partially neutralized with 0.5 mL of 3M sodium hydroxide in water. Analytical HPLC analysis (Waters OBondapak C-18 column; 97:3 = 0.1% acetic acid in wateπmethanol; flow rate: 1 mL/min) of this product indicated the production of radiochemically pure 6-[F-18]fluoro-L-dopa (22) in amounts usable for human PET studies.
[0066] The synthesis of specific examples of iodonium ylide precursors of amino acids are shown in Figures 7 and 8. These precursors demonstrate the usefulness and the protein nature of the nucleophilic F-18 fluorination process shown herein. Examples 12 and 13 describe the details pertaining to the preparation of specific amino acid based iodonium ylide precursors.
R1 = R2 = R3 = OCOOC(CH3)3, or
R1 = R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph, or R1 = H; R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph, or R1 = OCOOC(CH3)3 , OCH3 ; R2 = H and R3 = COCH3, COOCH2Ph, and X = CH2, O, S, NCH3, NCH2Ph and Y = CH2, C(CH3)2, =O can be prepared by hydrolyzing an ester group in protected L-iododopa or L-iodotyrosine analogs, cyclizing an amino acid group therein, oxidizing an iodo group therein into a diacetoxyiodo moiety and subsequently reacting the resultant compound with a cyclo 1,3- dicarbonyl derivative.
[0068] The resultant iodo compounds can then be converted to F- 18 chiral analogs as follows:
F- 18 chiral analogs having the formula:
can be prepared by the nucleophilic substitution of a iodonium ylide group in a chiral derivative having the formula
wherein:
R1 = R2 = R3 = OCOOC(CH3)3. or
R1 = R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph, or R1 = H; R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph or R1 = OCOOC(CH3)3 , OCH3 ; R2 = H and R3 = COCH3, COOCH2Ph, and X = CH2, O, S, NCH3, NCH2Ph and Y = CH2, C(CH3)2, =O by the nucleophilic substitution, using dry heating or microwave heating, of the iodonium ylide group in said chiral derivative, providing a dry, anhydrous no-carrier-added F-18 fluoride ion, said F-18 fluoride ion being derived from a [F-18]KF/Kryptofix complex, [F-18]CsF or quaternary ammonium fluoride, the quaternary ammonium groups being selected from tetramethyl, yetraethyl, tetra n-butyl, and tetrabenzyl.
[0069] F-18 labeled L-amino acids or D-amino acids having the formula:
wherein:
R4 = R5 = OH
R4 = H; R 5 = 0H
R4 = OH; R5 = H
can be prepared by acid hydrolysis of protected F-18 labeled D-chiral or L- chiral analogs respectively having the formula:
using mineral acids, such as HCI, HBr or HI, under dry heating or microwave heating conditions wherein
R1 = R2 = R3 = OCOOC(CH3)3> or
R1 = R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph, or R1 = H; R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph or R, = OCOOC(CH3)3 , OCH3, R2 = H and R3 = COCH3, COOCH2Ph.
[0070] Example 12 describes a procedure for preparing a specific compound in the manner described above
[0071] EXAMPLE 12
[0072] Figure 7 shows of forst embodiment of the reaction scheme for the synthesis of the oxazolidinone based iodonium ylide precursor.
[0073] a) N-(tert-butoxycarbonyl)-3,4-di(tert-butoxycarbonyloxy)-6-iodo-L- phenylalanine (23)
The iodo derivative 17 (3.5 mmol) (prepared as shown in Figure 6) was dissolved in 40 mL of THF and cooled in an ice bath (0°C) and a solution of lithium hydroxide (7.0 mmol) in 12 mL of water was added dropwise under argon. The resulting mixture was stirred at 00C for 4 h and then 2 h at room temperature. The reaction mixture was then neutralized with acetic acid to pH 5 and extracted with ethyl acetate. The organic phase was dried using Na2SO4, filtered and evaporated to dryness to provide an oil which was purified by silical gel column chromatography resulting in N-(tert-butoxycarbonyI)-3,4- di(tert-butoxycarbonyIoxy)-6-iodo-L-phenylalanine (23).
1H NMR (CDCl3): δ 7.76 (s, IH, ArH), 7.18 (s, I H, ArH), 5.07 (d, I H, NH), 4.60 (m,
IH), 3.12-3.40 (m, 2H5), 1.51 (s, 18H), 1.42 (s, 9H).
MS (MALDI): Calcd for C24H34INOi0 (M+): 623.12 ; Found: 645.93 (M++Na).
[0074] b) N-(tert-butoxycarbonyl)-l,3-oxazolidin-5-one derivative (24)
A mixture of the iodo amino acid 23 (0.86 mmol), camphorsulfonic acid (0.17 mmol), paraformaldehyde (1.29 mmol) and benzene (10 mL) was refluxed for 2 h. The mixture was diluted with ethyl acetate and was washed with 5% aqueous sodium bicarbonate solution. The organic phase was dried with anhydrous sodium sulfate, filtered and purified by silica gel column chromatography using 40% EtOAc/Hexane mixture as eluent to obtain pure oxazolidinone product 24 (N-(tert-butoxycarbonyl)-l,3-oxazolidin-
5-one derivative) as an oil in 35% yield.
1H NMR (CDCl3): δ 7.75 (s, IH, ArH), 7.15 (s, IH, ArH), 5.07 (d, IH, NH), 4.60 (m,
IH), 3.12-3.40 (m, 2H), 1.51 (s, 18H), 1.42 (s, 9H).
MS (MALDI): Calcd for C25H34INO10 (M+): 635.12 ; Found: 657.80 (M++Na).
[0075] c) Diacetoxyiodo N-(tert-butoxycarbonyl)-l,3-oxazolidin-5-one derivative (25). Thirty one mL of the DMDO reagent in acetone, prepared as described above, was added drop-wise to an ice cold solution of the iodo oxazolidin-5-one derivative 24 (0.31 mmol) in acetone-acetic acid (4: 1) (2.0 mL) and the solution was stirred at O0C in an ice bath under argon for 2 h. The ice bath was then removed and the reaction mixture was stirred at room temperature for 3 h. The solvents were evaporated under high vacuum to leave a diacetoxyiodo oxazolidinone analog 25 (Diacetoxyiodo N-(tert-butoxycarbonyl)-l,3- oxazolidin-5-one derivative) as an oil in 96.5% yield.
1H NMR (CDCl3): 6 8.15 (s, IH, ArH), 7.48 (s, IH, ArH), 4.98 (d, IH, NH), 4.60 (m, IH), 3.15-3.50 (m, 2H), 2.01 (s, 18H), 1.47 (s, 9H).
MS (MALDI): Calcd for C29H40INO14 (M+): 753.15 ; Found: 775.93 (M++Na). The product was used in the next step without further purification.
[0076] d) 2,2-Dimethyl-4,6-dioxo-l,3-dioxane iodonium ylide derivative 26 2,2-dimethyl-4,6-dioxo-l,3-dioxane (0.30 mmol) was added under argon to a solution of the iododiacetoxy oxazolidinone analog 25 (0.30 mmol) in anhydrous dichloromethane (6
mL) and the solution was stirred at room temperature overnight. The solvent was then evaporated and the product purified by flash chromatography on silica gel using 60-70% ethyl acetate in hexane as eluent to give the iodonium ylide 2,2-Dimethyl-4,6-dioxo-l,3- dioxane iodonium ylide derivative 26 as a white solid in 16 % yield.
1H NMR (CDCl3): δ 8.06 (s, IH, ArH), 7.29 (s, IH, ArH), 5.02 (d, IH, NH), 4.57 (m,
IH), 3.63-3.77 (m, 2H), 1.67 (s, 6H), 1.56 (s, 18H), 1.53 (s, 9H).
MS (MALDI): Calcd for C3IH40INOi4 (M+): 777.15 ; Found: 799.73 (M++Na).
[0077] In general, .iodonium ylide derivatives having the formula
R1 = R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or Rl = H and R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or Ri = OCH2Ph, OCOOC(CH3)3, OCH3 and R2 = H and X = CH2, O, S, NCH3, NCH2Ph Y = CH2, C(CH3)2, =O can be prepared by reacting:
with a chiral oxoimdazolidine auxiliary to produce a protected chiral amino acid derivatives, reacting the resultant compound with dimethyldioxirane in the presence of acetic acid to produce a diacetoxyiodo analog and subsequently reacting the diacetoxyiodo analog with a cyclol,3-dicarbonyl derivative.
[0078] Additionally, iodonium ylides having the formula
can be prepared by reacting
with a chiral pyrazine auxiliary to produce protected chiral amino acid derivatives, reacting the resultant compound with dimethyldioxirane in the presence of acetic acid to produce a diacetoxyiodo analog and subsequently reacting the diacetoxyiodo analog with the cyclol,3-dicarbonyl derivatives wherein:
R1 = R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or R 1 = H; R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or R1 = OCH2Ph, OCOOC(CHs)3, OCH3; R2 = H and X = CH2, O, S, NCH3, NCH2Ph Y = CH2, C(CH3)2, =0
[0079] #The resultant iodo compounds can then be converted to F- 18 chiral analogs having the formula
by using dry, anhydrous no-carrier-added F- 18 fluoride ion and dry heating or microwave heating where the F- 18 fluoride ion is derived from [F-18]KF/Kryptofix complex, [F- 18]CsF or quaternary ammonium fluoride, the quaternary ammonium groups selected from tetramethyl, yetraethyl, tetra n-butyl, and tetrabenzyl wherein
R1 = R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or R 1 = H; R2 = OCH2Ph, OCOOC(CH3)-,, OCH3 or R, = OCH2Ph, OCOOC(CH3)3, OCH3; R2 = H and X = CH2, O, S, NCH3, NCH2Ph and Y = CH2, C(CH3)2, =O
[0080] Additionally, resultant iodo compounds can be converted to F- 18 labeled L- amino acids having the formula
wherein:
R3 = R4 = OH
R3 = H; R4 = OH or
R3 = OH; R4 = H by the acid hydrolysis with mineral acids, such as HCl, HBr or HI, using dry heating or microwave heating of protected F- 18 labeled chiral analog s having the formula
wherein:
R1 = R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or
Rl = H; R2 = OCH2Ph, OCOOC(CH3)3, OCH3 Or
R, = OCH2Ph, OCOOC(CH-S)3, OCH3; R2 = H [0081] Example 13 is representative of such a reaction scheme. [0082] EXAMPLE 13
[0083] Figure 8 shows the reaction scheme for the synthesis of specific oxoimidazolidine and pyrazine based iodonium ylide precursors
[0084] a) 3, 4-Dibenzyloxybenzyl alcohol (28)
3,4-Dibenzyloxybenzaldehyde (27) (22.0 mmol) was suspended in 100 mL of anhydrous methanol and cooled to 00C under argon. Sodium borohydride (33.0 mmol) was added in portions to the suspension and stirred for 1 h at the same temperature. The resulting solution was then stirred at room temperature overnight. The reaction mixture was evaporated to dryness and the residue was dissolved in ice-water and neutralized with HCl. The solution was then extracted with chloroform and the organic layer was washed successively with water, 10% NaHCO3 solution in water and brine. The organic layer was dried over anhydrous Na2SO4, filtered and evaporated to dryness to provide pure 3,4- Dibenzyloxybenzyl alcohol (28) in 97.5 % yield.
1H NMR (CDCl3): δ 7.29-7.52 (m, 1OH, ArH), 7.02 (d, IH, ArH), 6.86-6.95 (dt, 2H, ArH), 5.19 (d, 4H), 4.59 (d, 2H).
[0085] b) 3,4-Dibenzyloxy-6-iodobenzyl alcohol (29)
The dibenzyloxybenzyl alcohol 28 (21.44 mmol) and silver trifluoroacetate (21.44 mmol) were suspended in 100 mL of dry chloroform and stirred under argon. A solution of iodine (21.44mmol) in dry chloroform (50 mL) was added to the suspension dropwise at
room temperature. The reaction mixture was then stirred for a further period of 2 h and filtered. The filtrate was washed with 20 % sodium thiosulfate solution in water. The organic layer was separated and dried over anhydrous Na2SO4. Filteration was followed by evaporation of the chloroform solution resulting in the pure iodo compound, 3,4-
Dibenzyloxy-6-iodobenzyl alcohol (29), as a pale yellow solid in 84 % yield.
1H NMR (CDCl3): δ 7.29-7.49 (m, 1 IH, ArH), 7.10 (s, IH, ArH), 5.15 (d, 4H), 4.59 (s,
2H).
MS (MALDI): Calcd for C21H19IO3 (M+): 446.04 ; Found: 468.98 (M++Na).
[0086] c) 3,4-Dibenzyloxy-6-iodobenzyl bromide (30)
A solution of the dibenzyloxy iodo alcohol derivative 29 (18.04mmol) in 100 mL of dichloromethane was added dropwise to an ice-cold hydrobromic acid (47-49% in water,
(72 mL) over a period of 90 min. The resulting yellow mixture was stirred for 30 min and then warmed slowly to room temperature. The reaction mixture was diluted with water and extracted with dichloromethane. The organic phase was dried over anhydrous
Na2SO4, filtered and evaporated to provide the bromo product, 3,4-Dibenzyloxy-6- iodobenzyl bromide (30) in quantitative yield.
1H NMR (CDCl3): δ 7.32-7.48 (m, 1 IH, ArH), 7.07 (s, IH, ArH), 5.15 (d, 4H), 4.54 (s,
2H).
[0087] d) (2S,5S)-tert-Butyl-5-(2'-iodo-4',5'-dibenzyloxybenzyl)-2-tert-butyl-3- methyl-4-oxoimidazolidine-l-carboxylate (31)
The carboxylate 31 was obtained using the general procedure reported in the literature [(D. Seebach, E. Dziadulewicz, L. Behrendt, S. Cantoreggi, R. Fitzi, "Synthesis of Nonproteinogenic (R)- or (S)-Amnio Acids Analogues of Phenylalanine, Isotopically Labelled and Cyclic Amino Acids from tert-Butyl 2-(tert-Butyl)-3-methyl-4-oxo-l- imidazolidinecarboxylate (Boc-BMI)." Liebigs Ann. Chem., pp 1215-1232 (1989)]. Thus, diisopropylamine (2.2 mmol) dissolved in dry THF (4 mL) was cooled to -40° C under argon and a solution of BuLi (2.5 M in hexane, 2.2 mmol) was added drop wise. After 30 min of stirring at -40° C, a solution of (S)-tert-butyl-2-tert-butyl-3-methyl-4-
oxoimidazolidine-1-carboxylate (2.2 mmol) was added drop wise and the reaction mixture was stirred for 30 min at - 40° C. A solution of the benzyl bromide (30) (2.2 mmol) in dry THF (6 mL) was then added drop wise to the reaction mixture. The new reaction mixture was stirred for 3 h at the same temperature and then poured into a saturated solution of NH4CI. The product was extracted with EtOAc and the organic layer was washed with NaHCO3 solution followed by brine. The organic phase was dried over anhydrous Na2SO4, filtered and evaporated to afford a yellow oil. Flash chromatographic purification of the oily product on a silica gel column with 6:1 hexane:ethyl acetate mixture provided pure (2S,5S)-tert-butyl-5-(2'-iodo-4',5'-dibenzyloxybenzyl)-2-tert- butyl-3-methyl-4-oxoimidazolidine-l-carboxylate (31) as a white solid in 32% yield. 1H NMR (CDCl3): δ 7.32-7.44 (m, 1 IH, ArH), 6.60 (s, IH, ArH), 5.09 (s, 4H), 4.95 (s, IH), 4.3 (t, IH), 3.44 (dd, 2H), 2.8 (s, 3H), 1.31 (s, 9H), 0.98 (s, 9H). MS (MALDI): Calcd for C34H41FN2O5 (M+): 684.21 ; Found: 707.07 (M++Na).
[0088] 2,2-Dimethyl-4,6-dioxo-l,3-dioxane iodonium ylide derivative 33
The iodo oxoimidazolidine derivative 31 (0.22 mmol) was first oxidized with dimethyldioxirane in the presence of acetic acid as described above to afford the corresponding diacetoxy intermediate analog in 84 % yield.
1H NMR (CDCl3): δ 7.76 (d, IH, ArH), 7. 47-7.36 (m, 1OH, ArH),7.05 (d, IH, ArH),
5.08-5.15 (m, 4H), 4.95 (s, IH), 4.3 (t, IH), 3.44 (dd, 2H), 3.03 (s, 3H), 2.1 1 (s, 6H5),
1.01 (s, 9H), 0.95 (s, 9H).
This diacetoxyiodo intermediate derivative can subsequently be converted to the the iodonium ylide 33 using the procedure given for the preparation of the analog 20.
[0089] 2,5-Dihydro-3,6-dimethoxy-2-isopropyl-5-(2'-iodo-4\5'-dibenzyloxybenzyl)- (2R,5S)-pyrazine (32)
[0090] The diastereomeric product 32 was obtained by a reaction of the lithium salt of the chiral auxiliary (2R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine with the bromo derivative 30 using a modification of a procedure reported in the literature [U. Schollkopf, "Enantioselective Synthesis of Non-Proteinogenic Amino Acids via
Metallated Bis-Lactim Ethers of 2,5-Diketopiperazines." Tetrahedron. 39, pp 2085-2091 (1983)]. Specifically, (2R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine (15.7 mmol) was dissolved in 10 mL of THF (freshly distilled from LiAlH4). The light yellow solution was cooled to -78° C (dry ice/acetone bath) and stirred for 15 min under argon. A 2.5 M solution of n-butyl lithium (15.7 mmol) was added drop wise over a period of 10 min and the mixture was stirred for 20 min at -78° C. In a separate flask CuCN (7.86 mmol) was stirred with 10 mL of freshly distilled THF at room temperature for 10 min. The white suspension was then cooled to 0° C (ice bath) and stirred at that temperature for 20 min. The n-BuLi reaction mixture was then transferred to the white suspension of CuCN/THF under argon using a cannula. The resulting yellow suspension turned into a yellow solution within two minutes. The reaction mixture was then stirred at 0° C for 15 min and cooled to -78° C. After 15 min of stirring at -78° C, a solution of bromo derivative 30 (7.86 mmol) in 20 mL of freshly distilled THF was added drop wise. The color of the reaction mixture changed to greenish brown. After stirring for a further period of 2 h at - 78° C, the reaction mixture was warmed gradually to room temperature. The reaction mixture was then poured into a saturated solution of NH4Cl and extracted with EtOAc. The organic phase was dried over anhydrous Na2SO4, filtered and evaporated to afford an oily compound which was purified by silica gel flash column chromatography eluting with 5 % ethyl acetate in hexane to yield pure 2,5-dihydro-3,6-dimethoxy-2-isopropyl-5- (2'-iodo-4',5'-dibenzyloxybenzyl)-(2R,5S)-pyrazine (32) as a white solid in 70% yield.
[0091] 2,2-Dimethyl-4,6-dioxo-l,3-dioxane iodonium ylide derivative 34 This ylide derivative can also be prepared from the iodo product 32, first by oxidizing it with DMDO reagent in the presence of acetic acid to give the corresponding diacetoxyiodo product which upon reaction with 2,2-dimethyl-4,6-dioxo-l,3-dioxane as described above will provide the analog, 2,2-Dimethyl-4,6-dioxo-l,3-dioxane iodonium ylide derivative 34.
[0092] The iodonium ylides 26, 33 and 34 can then be used as precursor materials for the preparation of 6-[F-18]fluoro-L-dopa in the manner described above. They can then
be reacted with [F- 18] fluoride ion as described above. The F- 18 labeled intermediates upon acid hydrolysis will yield 6-[F-18]fluoro-L-dopa. Further, the F-18 fluorinated D- and L- chiral amino acids can be prepared by starting with the appropriate D- and L- chiral precursors.
Claims
1. A procedure for preparing an F-18 labeled aryl derivative comprising: replacing the iodonium ylide group of a benzene derivative containing an iodonium ylide group with a no-carrier-added F-18 fluoride ion.
2. The procedure of claim 1 wherein the benzene derivative containing an iodonium ylide group is selected from the group comprising:
3. The procedure of claim 1 wherein the benzene derivative containing an iodonium ylide group is listed in the left hand column of the table below and the F- 18 containing any derivative produced therefrom is listed in the corresponding right hand column of the table below:
4. The procedure of claim 1 wherein the no-carrier-added [F-18]fluoride ion is produced by proton bombardment of [O- 18] water in a cyclotron body.
5. The procedure of claim 4 wherein: an aqueous solution containing the [F-18]fluoride ion is treated with potassium carbonate and a ligand or tetraalkylammonium bicarbonate, and the treated solution is evaporated to dryness to form a dry composition containing an [F-18]fluoride ion labeled compounds.
6. The procedure of claims 5 wherein the dry composition containing [F- 18]fluoride ion labeled compounds is reacted with the benzene derivative containing an iodonium ylide group to form an [F- 18] fluoroaryl derivative.
7. The procedure of claim 6 wherein the [F-18]fluoroaryl derivative is purified to produce a > 95 % radiochemical^ pure [F-18]fluoroaryl derivative.
8. The procedure of claim 6 wherein the [F-18]fluoroaryl derivative is purified to produce a > 99 % radiochemical^ and chemically pure product.
9. A procedure for preparing compounds labeled with a radiation emitting halogen moiety comprising: replacing the halogen group in an aryl derivative containing a pendent halogen group by an isotope ion of a halogen suitable for labeling purposes to form a radiation emitting halogen labeled aryl derivative, the radiation emitting ion being free of an ion carrier.
10. The procedure of claim 9 wherein the pendent halogen group is chloride or bromide.
11. 2,2-Dimethyl-4,6-dioxo-l,3-dioxan-5-[N-di(tert-butoxycarbonyl)-3,4-di- (tert-butoxycarbonyloxy)-L-phenylalanine ethyl ester-6-iodonium] ylide.
12. A process for producing 2,2-dimethyl-4,6-dioxo-l,3-dioxan-5-[N-di(tert- butoxycarbonyl)-3,4-di-(tert-butoxycarbonyloxy)-L-phenylalanine ethyl ester- 6-iodonium] ylide comprising:
(a) forming N-di(tert-butoxycarbonyl)-3,4-di-(tert-butoxycarbonyloxy)-6- iodo-L-phenylalanine ethyl ester by reacting N- (tert-butoxycarbonyl)- 3,4-di-(tert-butoxycarbonyloxy)-6-iodo-L-phenylalanine ethyl ester with di-tert-butyldicarbonate,
(b) reacting the product of step a) above with dimethyldioxirane in acetone-acetic acid mixture to form N-di(tert-butoxycarbonyl)-3,4-di- (tert-butoxycarbonyloxy)-6-(diacetoxy)iodo-L-phenylalanine ethyl ester, and
(c) exposing the product of step b) above to 2,2-dimethyl-4,6-dioxo-l,3- dioxane to form 2,2-dimethyl-4,6-dioxo-l,3-dioxan-5-[N-di(tert- butoxycarbonyl)-3,4-di-(tert-butoxycarbonyloxy)-L-phenylalanine- ethyl ester-6-iodonium] ylide.
13. A process for forming 6-[F-18]fluoro-L-dopa comprising:
(a) preparing an F- 18 labeled aryl derivative comprising: replacing the iodonium ylide group of a benzene derivative containing an iodonium ylide group with a no-carrier-added F- 18 fluoride ion, said no-carrier- added [F-18]fluoride ion being produced by proton bombardment of [O- 18] water in a cyclotron body, treating an aqueous solution containing the [F-18]fluoride ion with potassium carbonate and a ligand or tetraalkylammonium bicarbonate, and evaporating the treated solution to dryness to form a dry composition containing an [F-18]fluoride ion labeled compounds.
(b) reacting 2,2-dimethyl-4,6-dioxo-l,3-dioxan-5-[N-di(tert-butoxycarbonyl)- 3,4-di-(tert-butoxycarbonyloxy)-L-phenylalanine ethyl ester-6-iodonium] ylide with the dry composition containing the [F-18]fluoride ion labeled compounds, and
(c) treating the product of step b) above with a halogen acid.
14. A compound having the formula:
wherein Ri and R2 are hydroxyl protecting lower alkyl (methyl, ethyl) groups or benzyl or tert-butoxycarbonyl groups,
R3 and R4 are amine protecting acetoxy, trifluoroacetoxy or tert- butoxycarbonyloxy groups,
R5 is carboxylic acid protecting methyl, ethyl, tert-butyl, or benzyl groups,
X = CH2, O, S, NCH3, NCH2Ph and
Y = CH2, C(CH3)2, C=O
15. The compound of claim 14 where Ri and R2 are (CH3)3COCO, R3 and R4 are (CH3)3COCO, X = O and Y = C(CH3)2 .
16. A procedure for the preparation of iodonium ylide analogs having the formula:
R1 = R2 = R3 = OCOOC(CH3)-,, or
R1 = R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph, or R, = H; R2 = OCOOC(CH3)-, , OCH3 and R3 = COCH3, COOCH2Ph, or R1 = OCOOC(CH3)3 , OCH3 ; R2 = H and R3 = COCH3, COOCH2Ph, and X = CH2, O, S, NCH3, NCH2Ph and Y = CH2, C(CH3)2, =O comprising: hydrolyzing an ester group in a protected L-iododopa or L-iodotyrosine analogs, cyclizing an amino acid group therein, oxidizing an iodo group therein into a diacetoxyiodo moiety and subsequently reacting the resultant compound with a cyclo 1,3-dicarbonyl derivative.
17. A method for the production of F-18 chiral analogs having the formula:
comprising the nucleophilic substitution of an iodonium ylide group in a chiral derivative having the formula
R. = R2 = R3 = OCOOC(CH3)3 or R1 = R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph, or R, = H; R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph or R, = OCOOC(CH3)3 , OCH3 ; R2 = H and R3 = COCH3, COOCH2Ph, and X = CH2, O, S, NCH3, NCH2Ph and Y = CH2, C(CH3)2, =O using dry heating or microwave heating for the nucleophilic substitution of the iodonium ylide group in said chiral derivative, providing a dry, anhydrous no- carrier-added F- 18 fluoride ion, said F- 18 fluoride ion being derived from a [F-18]KF/Kryptofix complex, [F-18]CsF or quaternary ammonium fluoride, the quaternary ammonium groups being selected from tetramethyl, yetraethyl, tetra n-butyl, and tetrabenzyl.
18. A method of producing F- 18 labeled L-amino acids or D-amino acids having the formula:
wherein:
R4 = R5 = OH
R4 = H; R 5 = OH
R4 = OH; R5 = H
comprising the acid hydrolysis of protected F- 18 labeled D-chiral or L- chiral analogs respectively having the formula:
R1 = R2 = R3 = OCOOC(CH3K or
R1 = R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph, or R, = H; R2 = OCOOC(CH3)3 , OCH3 and R3 = COCH3, COOCH2Ph or R1 = OCOOC(CH3)3 , OCH3, R2 = H and R3 = COCH3, COOCH2Ph.
19. A procedure for the preparation of iodonium ylide derivatives having the formula
wherein:
R, = R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or
Rl = H and R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or
R1 = OCH2Ph, OCOOC(CH3)3, OCH3 and R2 = H and
X = CH2, O, S, NCH3, NCH2Ph
Y = CH2, C(CH3)2, =0 comprising reacting:
with a chiral oxoimdazolidine auxiliary to produce a protected chiral amino acid derivatives, reacting the resultant compound with dimethyldioxirane in the presence of acetic acid to produce a diacetoxyiodo analog and subsequently reacting the diacetoxyiodo analog with a cyclol,3-dicarbonyl derivative.
20. A method for the production of F-18 chiral compounds having the formula
comprising the nucleophilic substitution of the iodonium ylide group in a chiral derivative having the formula
with dry/anhydrous no-carrier-added F- 18 fluoride ion using dry heating or microwave heating where the F- 18 fluoride ion is derived from [F- 18]KF/Kryptofix complex, [F-18]CsF or quaternary ammonium fluoride, the quaternary ammonium group being selected from tetramethyl, yetraethyl, tetra n- butyl, and tetrabenzyl and
R, = R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or
Rl = H and R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or
R, = OCH2Ph, OCOOC(CH3)3) OCH3 and R2 = H and
X = CH2, O, S, NCH3, NCH2Ph and
Y = CH2, C(CH3)2, =O
wherein:
R3 = R4 = OH or
R3 = H; R4 = OH or
R3 = OHj R4 = H comprising acid hydrolysis, using mineral acids selected from the group consisting of HCl, HBr or HI, under dry heating or microwave heating conditions of protected F- 18 labeled L-chiral or D-chiral analogs, respectively having the formula:
wherein:
R1 = R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or
Rl = H and R2 = OCH2Ph, OCOOC(CH3)3, OCH3, or
R, = OCH2Ph, OCOOC(CH3):,, OCH3 and R2 = H
22. A procedure for the preparation of the iodonium ylides having the formula
comprising: reacting with a chiral pyrazine auxiliary to produce protected chiral amino acid derivatives, reacting the resultant compound with dimethyldioxirane in the presence of acetic acid to produce a diacetoxyiodo analog and subsequently reacting the diacetoxyiodo analog with the cyclol,3- dicarbonyl derivatives wherein:
R1 = R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or
Rl = H; R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or
Ri = OCH2Ph, OCOOC(CH3)3, OCH3; R2 = H and
X = CH2, O, S, NCH3, NCH2Ph and
Y = CH2, C(CH3)2) =0
23. A method for the production of F-18 chiral analogs having the formula
comprising the nucleophilic substitution of the iodonium ylide group in a chiral analog having the formula:
with dry/anhydrous no-carrier-added F-18 fluoride ion using dry heating or microwave heating where the F-18 fluoride ion is derived from [F- 18] KF/Kryptofix complex, [F-18]CsF or quaternary ammonium fluoride, the quaternary ammonium groups selected from tetramethyl, yetraethyl, tetra n-butyl, and tetrabenzyl wherein
R, = R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or
Rl = H; R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or
R, = OCH2Ph, OCOOC(CH3)3, OCH3; R2 = H and
X = CH2, O, S, NCH3, NCH2Ph and
Y = CH2, C(CH3)2, =O
24. A method for producing F- 18 labeled L-amino acids having the formula
wherein:
R3 = R4 = OH
R3 = H; R4 = OH or
R3 = OH; R4 = H
comprising acid hydrolysis with mineral acids selected from the group consisting of HCl, HBr or HI under dry heating or microwave heating conditions of a protected F- 18 labeled chiral analog having the formula
Ri = R2 = OCH2Ph, OCOOC(CH3)3, OCH3 or
Rl = H; R 2 = OCH2Ph, OCOOC(CH3)3, OCH3 or R1 = OCH2Ph, OCOOC(CH3)3, OCH3; R2 = H
25. The processes or methods of claim 12, 17, 20 or 23 for the preparation of a) iodonium ylide containing amino acids having a D-configuration comprising utilizing D-chiral precursors, or b) iodonium ylide containing amino acids having an L-configuration comprising utilizing-L-chiral precursors.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US13/263,333 US8742139B2 (en) | 2009-04-08 | 2010-04-01 | No-carrier-added nucleophilic [F-18] fluorination of aromatic compounds |
EP10761972.8A EP2417119B1 (en) | 2009-04-08 | 2010-04-01 | No-carrier-added nucleophilic ýf-18¨fluorination of aromatic compounds |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US16783209P | 2009-04-08 | 2009-04-08 | |
US61/167,832 | 2009-04-08 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2010117435A2 true WO2010117435A2 (en) | 2010-10-14 |
WO2010117435A3 WO2010117435A3 (en) | 2011-03-31 |
Family
ID=42936763
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2010/001012 WO2010117435A2 (en) | 2009-04-08 | 2010-04-01 | No-carrier-added nucleophilic [f-18] fluorination of aromatic compounds |
Country Status (3)
Country | Link |
---|---|
US (1) | US8742139B2 (en) |
EP (1) | EP2417119B1 (en) |
WO (1) | WO2010117435A2 (en) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140121371A1 (en) * | 2012-10-27 | 2014-05-01 | Ground Fluor Pharmaceuticals, Inc. | Processes and reagents for making diaryliodonium salts |
US20160362375A1 (en) * | 2014-03-07 | 2016-12-15 | The General Hospital Corporation | Iodine(III)-Mediated Radiofluorination |
US10259800B2 (en) | 2015-10-29 | 2019-04-16 | The General Hospital Corporation | Method of fluorination using iodonium ylides |
WO2019192912A1 (en) * | 2018-04-06 | 2019-10-10 | Rigshospitalet | 1-step radiosynthesis of [18f]sfb |
Families Citing this family (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2014183130A1 (en) * | 2013-05-10 | 2014-11-13 | The Regents Of The University Of California | Synthesis of fluorinated radiopharmaceuticals via electrochemical fluorination |
WO2018075685A1 (en) | 2016-10-18 | 2018-04-26 | The Regents Of The University Of California | Method for positron emission tomography (pet) imaging analysis for classifying and diagnosing of neurological diseases |
WO2018089491A1 (en) | 2016-11-08 | 2018-05-17 | The Regents Of The University Of California | Methods for multi-dose synthesis of [f-18]fddnp for clinical settings |
CN109384806B (en) * | 2017-08-03 | 2021-04-27 | 王璐 | A [ 2 ]18F]Novel preparation method of FBPA (FBPA) |
AU2021223942A1 (en) * | 2020-02-21 | 2022-10-13 | National University Corporation Hokkaido University | Method for producing aromatic astatine compound |
WO2022114333A1 (en) * | 2020-11-30 | 2022-06-02 | 가천대학교 산학협력단 | Method for efficient production of 2-[18f]fluoro-4-boronophenylalanine comprising radioisotopes |
CN115160167A (en) * | 2022-08-08 | 2022-10-11 | 江苏华益科技有限公司 | In accordance with GMP standard 18 Novel preparation method of F-FDOPA |
Family Cites Families (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU571325B2 (en) * | 1984-05-04 | 1988-04-14 | Dow Chemical Company, The | Iodonium ylide compositions and method for antimicrobial use |
US5254726A (en) * | 1991-06-07 | 1993-10-19 | The United States Of America As Represented By The Department Of Energy | No-carrier-added (NCA) aryl (18E) fluorides via the nucleophilic aromatic substitution of electron rich aromatic rings |
GB0329716D0 (en) * | 2003-12-23 | 2004-01-28 | Amersham Plc | Radical trap |
-
2010
- 2010-04-01 WO PCT/US2010/001012 patent/WO2010117435A2/en active Application Filing
- 2010-04-01 US US13/263,333 patent/US8742139B2/en not_active Expired - Fee Related
- 2010-04-01 EP EP10761972.8A patent/EP2417119B1/en not_active Not-in-force
Non-Patent Citations (3)
Title |
---|
M. CARROLL; C. JONES; S.-L. TANG: "Fluoridation of 2-thienyliodonium salts", J. LABEL. COMPD. RADIOPHARM, vol. 50, 2007, pages 450 - 451, XP002535854, DOI: doi:10.1002/JLCR.1189 |
See also references of EP2417119A4 |
T.L. ROSS; J. ERMERT; C. HOCKE; H.H. COENEN: "Nucleophilic 1 8F-Fluori nation of Heteroaromatic Iodonium Salts with No-Carrier-Added [18 F]Fluoride.", J.AM. CHEM. SOC., vol. 129, 2007, pages 8018 - 8025 |
Cited By (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20140121371A1 (en) * | 2012-10-27 | 2014-05-01 | Ground Fluor Pharmaceuticals, Inc. | Processes and reagents for making diaryliodonium salts |
JP2016503401A (en) * | 2012-10-27 | 2016-02-04 | グランド・フルーア・ファーマスーティカルズ・インコーポレイテッド | Methods and reagents for producing diaryliodonium salts |
US20160362375A1 (en) * | 2014-03-07 | 2016-12-15 | The General Hospital Corporation | Iodine(III)-Mediated Radiofluorination |
CN106458960A (en) * | 2014-03-07 | 2017-02-22 | 通用医疗公司 | Iodine(III)-mediated radiofluorination |
EP3114117A4 (en) * | 2014-03-07 | 2017-08-09 | The General Hospital Corporation | Iodine(iii)-mediated radiofluorination |
US9957231B2 (en) | 2014-03-07 | 2018-05-01 | The General Hospital Corporation | Iodine(II)-mediated radiofluorination |
CN106458960B (en) * | 2014-03-07 | 2020-10-23 | 通用医疗公司 | Iodine (III) -mediated radiofluorination |
CN112094259A (en) * | 2014-03-07 | 2020-12-18 | 通用医疗公司 | Iodine (III) -mediated radiofluorination |
CN112094259B (en) * | 2014-03-07 | 2023-09-01 | 通用医疗公司 | Iodine (III) -mediated radiofluorination |
US10259800B2 (en) | 2015-10-29 | 2019-04-16 | The General Hospital Corporation | Method of fluorination using iodonium ylides |
WO2019192912A1 (en) * | 2018-04-06 | 2019-10-10 | Rigshospitalet | 1-step radiosynthesis of [18f]sfb |
Also Published As
Publication number | Publication date |
---|---|
US8742139B2 (en) | 2014-06-03 |
US20120123120A1 (en) | 2012-05-17 |
WO2010117435A3 (en) | 2011-03-31 |
EP2417119A2 (en) | 2012-02-15 |
EP2417119B1 (en) | 2016-12-21 |
EP2417119A4 (en) | 2014-05-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2417119B1 (en) | No-carrier-added nucleophilic ýf-18¨fluorination of aromatic compounds | |
EP2307337B1 (en) | Nucleophilic fluorination of aromatic compounds | |
CA2629227C (en) | Precursor compound of radioactive halogen-labeled organic compound | |
US11884619B2 (en) | Reagents and methods for esterification | |
EP2238139B1 (en) | Method for preparing a marked purine derivative, said derivative and uses thereof | |
EP2464637A1 (en) | Sultone compound derivatives substituted by nucleophiles, in particular radionuclides, and use thereof for marking macromolecules | |
EP2746250B1 (en) | Precursors and process for the production of 18F-labelled amino acids | |
KR100458983B1 (en) | Processes for preparing an optically active serine derivative | |
US20140012005A1 (en) | Process for preparing chiral amino acids | |
MX2013015239A (en) | DIRECT SYNTHESIS OF 18F-FLUOROMETHOXY COMPOUNDS FOR PET IMAGING AND THE PROVISION OF NEW PRECURSORS FOR DIRECT RADIOSYNTHESIS OF PROTECTED DERIVATIVES OF O-([18</s up>F]FLUOROMETHYL) TYROSINE. | |
EP2792664B1 (en) | Optical resolution method for bicyclic compound using asymmetric catalyst | |
Rong et al. | Aliphatic [18F] Fluorination Chemistry for Positron Emission Tomography | |
ES2829253T3 (en) | Resolution of racemic beta-aminosulfone compounds | |
Rabasa-Alcañiz et al. | Asymmetric synthesis of polycyclic 3-fluoroalkylproline derivatives by intramolecular azomethine ylide cycloaddition | |
JP2020011928A (en) | 4-boronophenylalanine precursor, method for producing 2-[18f]fluoro-4-boronophenylalanine precursor, and method for producing 2-[18f]fluoro-4-boronophenylalanine | |
US20170036980A1 (en) | Copper catalyzed [18f]fluorination of iodonium salts | |
US20100261913A1 (en) | Method for producing precursors for l-3,4-dihydroxy-6- [18f] fluorophenyl alaine and 2- [18f] fluoro-l-tyrosine and the alpha-methylated derivatives thereof, precursor, and method for producing l-3, 4dihydroxy-6- [18f] fluorophenylalanine and 2- [18f] fluoro-l-tyrosine and the alpha-methylated derivatives from the precursor | |
KR101619564B1 (en) | Novel precursor molecules for f-18 labelled pet tracers | |
US20210205482A1 (en) | Method for preparing fluorine-18-labeled fluoromethyl-substituted radiopharmaceuticals using selective azide substitution reaction and precursor scavenging | |
US6872855B1 (en) | Method for expedient synthesis of [18F]-labeled α-trifluoromethyl ketones | |
Sarkar | Novel synthetic reactions employing hypervalent iodine compounds: oxidations and arylations | |
Hu et al. | Aminosulfur Trifluoride Deoxofluorination | |
US20160317682A1 (en) | PREPARATION OF Ag18F AND ITS USE IN THE SYNTHESIS OF PET RADIOTRACERS | |
JP6084570B2 (en) | Method for producing 3,4-dihydroisoquinoline derivative | |
Cui et al. | Ar-SF4Cl Deoxofluorination |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 10761972 Country of ref document: EP Kind code of ref document: A2 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
REEP | Request for entry into the european phase |
Ref document number: 2010761972 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2010761972 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 13263333 Country of ref document: US |